Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Eric Topol

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Recurrence

Devices

Stents

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
311
Califf, Robert
143
Ellis, Stephen
125
Lincoff, Michael
75
Bhatt, Deepak
73
Harrington, Robert
71
Kereiakes, Dean
71
Granger, Christopher
65
Moliterno, David
61
White, Harvey
59
Ohman, Magnus
51
Simoons, Maarten
46
Van de Werf, Frans
44
Kleiman, Neal
41
Armstrong, Paul
39
Bates, Eric

Sign-in to see all Coauthors

Publications

TOP 3
Berger Jeffrey S; Bhatt Deepak L; Cannon Christopher P; Chen Zhengming; Jiang Lixin; Jones James B; Mehta Shamir R; Sabatine Marc S; Steinhubl Steven R; Topol Eric J; Berger Peter B
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
Tewhey Ryan; Warner Jason B; Nakano Masakazu; Libby Brian; Medkova Martina; David Patricia H; Kotsopoulos Steve K; Samuels Michael L; Hutchison J Brian; Larson Jonathan W; Topol Eric J; Weiner Michael P; Harismendy Olivier; Olson Jeff; Link Darren R; Frazer Kelly A
Microdroplet-based PCR enrichment for large-scale targeted sequencing.
Herrmann Howard C; Lu Jiandong; Brodie Bruce R; Armstrong Paul W; Montalescot Gilles; Betriu Amadeo; Neuman Franz-Joseph; Effron Mark B; Barnathan Elliot S; Topol Eric J; Ellis Stephen G;
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Eric Topol (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Berger Jeffrey S; Bhatt Deepak L; Cannon Christopher P; Chen Zhengming; Jiang Lixin; Jones James B; Mehta Shamir R; Sabatine Marc S; Steinhubl Steven R; Topol Eric J; Berger Peter B
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
Journal of the American College of Cardiology 2009;54(21):1935-45.
2009: Tewhey Ryan; Warner Jason B; Nakano Masakazu; Libby Brian; Medkova Martina; David Patricia H; Kotsopoulos Steve K; Samuels Michael L; Hutchison J Brian; Larson Jonathan W; Topol Eric J; Weiner Michael P; Harismendy Olivier; Olson Jeff; Link Darren R; Frazer Kelly A
Microdroplet-based PCR enrichment for large-scale targeted sequencing.
Nature biotechnology 2009;27(11):1025-31.
2009: Herrmann Howard C; Lu Jiandong; Brodie Bruce R; Armstrong Paul W; Montalescot Gilles; Betriu Amadeo; Neuman Franz-Joseph; Effron Mark B; Barnathan Elliot S; Topol Eric J; Ellis Stephen G;
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.
JACC. Cardiovascular interventions 2009;2(10):917-24.
2009: Ellis Stephen G; Tendera Michal; de Belder Mark A; van Boven Ad J; Widimsky Petr; Andersen Henning R; Betriu Amadeo; Savonitto Stefano; Adamus Jerzy; Peruga Jan Z; Hamankiewicz Maciej; Pluta Waladyslaw; Oldroyd Keith; Ecollan Patrick; Janssens Luc; Armstrong Paul; Brodie Bruce R; Herrmann Howard C; Montalescot Gilles; Neumann Franz-Josef; Effron Mark B; Barnathan Elliot S; Topol Eric J;
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.
JACC. Cardiovascular interventions 2009;2(10):909-16.
2009: Joyner Alexander H; J Cooper Roddey; Bloss Cinnamon S; Bakken Trygve E; Rimol Lars M; Melle Ingrid; Agartz Ingrid; Djurovic Srdjan; Topol Eric J; Schork Nicholas J; Andreassen Ole A; Dale Anders M
A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(36):15483-8.
2009: Chen Jersey; Bhatt Deepak L; Dunn Elizabeth Schneider; Shi Chunxue; Caro J Jaime; Mahoney Elizabeth M; Gabriel Sylvie; Jackson Joseph D; Topol Eric J; Cohen David J
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009;12(6):872-9.
2009: Berger Jeffrey S; Elliott Laine; Gallup Dianne; Roe Matthew; Granger Christopher B; Armstrong Paul W; Simes R John; White Harvey D; Van de Werf Frans; Topol Eric J; Hochman Judith S; Newby L Kristin; Harrington Robert A; Califf Robert M; Becker Richard C; Douglas Pamela S
Sex differences in mortality following acute coronary syndromes.
JAMA : the journal of the American Medical Association 2009;302(8):874-82.
2009: Collet Jean-Philippe; Montalescot Gilles; Steg Philippe Gabriel; Steinhubl Steven R; Fox Keith A A; Hu Ting Fei; Johnston S Claiborne; Hamm Christian W; Bhatt Deepak L; Topol Eric J
Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.
Archives of cardiovascular diseases 2009;102(6-7):485-96.
2009: Schork Nicholas J; Murray Sarah S; Frazer Kelly A; Topol Eric J
Common vs. rare allele hypotheses for complex diseases.
Current opinion in genetics & development 2009;19(3):212-9.
2009: Dasgupta Arijit; Steinhubl Steven R; Bhatt Deepak L; Berger Peter B; Shao Mingyuan; Mak Koon-Hou; Fox Keith A A; Montalescot Gilles; Weber Michael A; Haffner Steven M; Dimas Alexios P; Steg P Gabriel; Topol Eric J;
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
The American journal of cardiology 2009;103(10):1359-63.
2009: Price Matthew J; Berger Peter B; Angiolillo Dominick J; Teirstein Paul S; Tanguay Jean-François; Kandzari David E; Cannon Christopher P; Topol Eric J
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
American heart journal 2009;157(5):818-24, 824.e1.
2009: Topol Eric J
Past the wall in cardiovascular R&D.
Nature reviews. Drug discovery 2009;8(4):259.
2009: Mak Koon-Hou; Bhatt Deepak L; Shao Mingyuan; Hankey Graeme J; Easton J Donald; Fox Keith A A; Topol Eric J
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
American heart journal 2009;157(4):658-65.
2009: Frazer Kelly A; Murray Sarah S; Schork Nicholas J; Topol Eric J
Human genetic variation and its contribution to complex traits.
Nature reviews. Genetics 2009;10(4):241-51.
2009: Mak Koon-Hou; Bhatt Deepak L; Shao Mingyuan; Haffner Steven M; Hamm Christian W; Hankey Graeme J; Johnston S Claiborne; Montalescot Gilles; Steg Philippe Gabriel; Steinhubl Steven R; Fox Keith A A; Topol Eric J
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
European heart journal 2009;30(7):857-65.
2009: Steinhubl Steven R; Bhatt Deepak L; Brennan Danielle M; Montalescot Gilles; Hankey Graeme J; Eikelboom John W; Berger Peter B; Topol Eric J;
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Annals of internal medicine 2009;150(6):379-86.
2009: Aronow Herbert D; Steinhubl Steven R; Brennan Danielle M; Berger Peter B; Topol Eric J;
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
American heart journal 2009;157(2):369-74.
2009: Robertson Jason O; Li Wei; Silverstein Roy L; Topol Eric J; Smith Jonathan D
Deficiency of LRP8 in mice is associated with altered platelet function and prolonged time for in vivo thrombosis.
Thrombosis research 2009;123(4):644-52.
2009: Shishehbor Mehdi H; Madhwal Surabhi; Rajagopal Vivek; Hsu Amy; Kelly Peter; Gurm Hitinder S; Kapadia Samir R; Lauer Michael S; Topol Eric J
Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction.
JACC. Cardiovascular interventions 2009;2(1):46-53.
2009: Cacoub Patrice P; Bhatt Deepak L; Steg P Gabriel; Topol Eric J; Creager Mark A;
Patients with peripheral arterial disease in the CHARISMA trial.
European heart journal 2009;30(2):192-201.
2009: Van de Werf F J; Topol E J; Sobel B E
The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction.
Journal of thrombosis and haemostasis : JTH 2009;7(1):14-20.
2009: Damani Samir B; Topol Eric J
Molecular genetics of atrial fibrillation.
Genome medicine 2009;1(5):54.
2009: Harismendy Olivier; Ng Pauline C; Strausberg Robert L; Wang Xiaoyun; Stockwell Timothy B; Beeson Karen Y; Schork Nicholas J; Murray Sarah S; Topol Eric J; Levy Samuel; Frazer Kelly A
Evaluation of next generation sequencing platforms for population targeted sequencing studies.
Genome biology 2009;10(3):R32.
2008: Aronow Herbert D; Califf Robert M; Harrington Robert A; Vallee Marc; Graffagnino Carmelo; Shuaib Ashfaq; Fitzgerald Desmond J; Easton J Donald; Van de Werf Frans; Diener Hans-Christoph; Ferguson James; Koudstaal Peter J; Amarenco Pierre; Theroux Pierre; Davis Stephen; Topol Eric J
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
The American journal of cardiology 2008;102(10):1285-90.
2008: Aronow Herbert D; Lincoff A Michael; Quinn Martin J; McRae A Thomas; Gurm Hitinder S; Houghtaling Penny L; Granger Christopher B; Harrington Robert A; Van de Werf Franz; Topol Eric J; Lauer Michael S;
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
The American journal of cardiology 2008;102(9):1119-24.
2008: Torkamani Ali; Topol Eric J; Schork Nicholas J
Pathway analysis of seven common diseases assessed by genome-wide association.
Genomics 2008;92(5):265-72.
2008: Topol Eric J
Genome scanning and cardiovascular disease.
Heart (British Cardiac Society) 2008;94(11):1361-3.
2008: Eikelboom John W; Hankey Graeme J; Thom Jim; Bhatt Deepak L; Steg P Gabriel; Montalescot Gilles; Johnston S Claiborne; Steinhubl Steven R; Mak Koon-Hou; Easton J Donald; Hamm Christian; Hu Tingfei; Fox Keith A A; Topol Eric J;
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Circulation 2008;118(17):1705-12.
2008: Musunuru Kiran; Kral Brian G; Blumenthal Roger S; Fuster Valentin; Campbell Catherine Y; Gluckman Ty J; Lange Richard A; Topol Eric J; Willerson James T; Desai Milind Y; Davidson Michael H; Mora Samia
The use of high-sensitivity assays for C-reactive protein in clinical practice.
Nature clinical practice. Cardiovascular medicine 2008;5(10):621-35.
2008: Abdullah K G; Li L; Shen G-Q; Hu Y; Yang Y; MacKinlay K G; Topol E J; Wang Q K
Four SNPS on chromosome 9p21 confer risk to premature, familial CAD and MI in an American Caucasian population (GeneQuest).
Annals of human genetics 2008;72(Pt 5):654-7.
2008: Murray Sarah S; Topol Eric J
Gaining insights in coronary disease genomics.
Journal of the American College of Cardiology 2008;52(5):385-6.
2008: Ellis Stephen G; Tendera Michal; de Belder Mark A; van Boven Ad J; Widimsky Petr; Janssens Luc; Andersen H R; Betriu Amadeo; Savonitto Stefano; Adamus Jerzy; Peruga Jan Z; Kosmider Maciej; Katz Olivier; Neunteufl Thomas; Jorgova Julia; Dorobantu Maria; Grinfeld Liliana; Armstrong Paul; Brodie Bruce R; Herrmann Howard C; Montalescot Gilles; Neumann Franz-Josef; Effron Mark B; Barnathan Elliot S; Topol Eric J;
Facilitated PCI in patients with ST-elevation myocardial infarction.
The New England journal of medicine 2008;358(21):2205-17.
2008: Sabatine Marc S; Hamdalla Hussam N; Mehta Shamir R; Fox Keith A A; Topol Eric J; Steinhubl Steven R; Cannon Christopher P
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
American heart journal 2008;155(5):910-7.
2008: Elias Darlene J; Topol Eric J
Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin.
European journal of human genetics : EJHG 2008;16(5):532-4.
2008: Seidelmann Sara Bretschger; Li Lin; Shen Gong-Qing; Topol Eric J; Wang Qing Kenneth
Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MI.
Journal of lipid research 2008;49(5):1034-8.
2008: Suhar Christopher J; Hitchcock Todd M; Russo Robert J; Topol Eric J
Is computed tomographic angiography prognostic in patients with cardiac symptoms?
Journal of the American College of Cardiology 2008;51(15):1510; author reply 1510-1.
2008: Best Patricia J M; Steinhubl Steven R; Berger Peter B; Dasgupta Arijit; Brennan Danielle M; Szczech Lynda A; Califf Robert M; Topol Eric J;
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
American heart journal 2008;155(4):687-93.
2008: Bhattacharyya Tamali; Nicholls Stephen J; Topol Eric J; Zhang Renliang; Yang Xia; Schmitt David; Fu Xiaoming; Shao Mingyuan; Brennan Danielle M; Ellis Stephen G; Brennan Marie-Luise; Allayee Hooman; Lusis Aldons J; Hazen Stanley L
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.
JAMA : the journal of the American Medical Association 2008;299(11):1265-76.
2008: Jozic Joseph; Orford James; Steinhubl Steven; Berger Peter; Hsu Amy; Topol Eric
Timing and correlates of very early major adverse clinical events following percutaneous coronary intervention.
The Journal of invasive cardiology 2008;20(3):113-8.
2008: Inrig Jula K; Patel Uptal D; Briley Libbie P; She Lilin; Gillespie Barbara S; Easton J Donald; Topol Eric J; Szczech Lynda A
Mortality, kidney disease and cardiac procedures following acute coronary syndrome.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2008;23(3):934-40.
2008: Hart Robert G; Bhatt Deepak L; Hacke Werner; Fox Keith A A; Hankey Graeme J; Berger Peter B; Hu Tingfei; Topol Eric J;
Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Cerebrovascular diseases (Basel, Switzerland) 2008;25(4):344-7.
2007: Damani Samir B; Topol Eric J
Future use of genomics in coronary artery disease.
Journal of the American College of Cardiology 2007;50(20):1933-40.
2007: Feit Frederick; Voeltz Michele D; Attubato Michael J; Lincoff A Michael; Chew Derek P; Bittl John A; Topol Eric J; Manoukian Steven V
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.
The American journal of cardiology 2007;100(9):1364-9.
2007: Inrig Jula K; Gillespie Barbara S; Patel Uptal D; Briley Libbie P; She Lilin; Easton J Donald; Topol Eric; Szczech Lynda A
Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate.
Clinical journal of the American Society of Nephrology : CJASN 2007;2(6):1215-22.
2007: Patay Bradley A; Topol Eric J
Is there a genetic basis for acute coronary syndrome?
Nature clinical practice. Cardiovascular medicine 2007;4(11):596-7.
2007: Singh Mandeep; White Jennifer; Hasdai David; Hodgson Patricia K; Berger Peter B; Topol Eric J; Califf Robert M; Holmes David R
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial.
Journal of the American College of Cardiology 2007;50(18):1752-8.
2007: Reynolds Harmony R; Farkouh Michael E; Lincoff A Michael; Hsu Amy; Swahn Eva; Sadowski Zygmunt P; White Jennifer A; Topol Eric J; Hochman Judith S;
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V.
Archives of internal medicine 2007;167(19):2054-60.
2007: McCarthy Jeanette J; Topol Eric J
Validity of reported genetic risk factors for acute coronary syndrome.
JAMA : the journal of the American Medical Association 2007;298(15):1758; author reply 1759.
2007: Karp Igor; Topol Eric; Pilote Louise
Population attributable fraction: its implications for genetic epidemiology and illness prevention.
American heart journal 2007;154(4):607-9.
2007: Shen Gong-Qing; Li Lin; Girelli Domenico; Seidelmann Sara B; Rao Shaoqi; Fan Chun; Park Jeong Euy; Xi Quansheng; Li Jing; Hu Ying; Olivieri Oliviero; Marchant Kandice; Barnard John; Corrocher Roberto; Elston Robert; Cassano June; Henderson Susan; Hazen Stanley L; Plow Edward F; Topol Eric J; Wang Qing K
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction.
American journal of human genetics 2007;81(4):780-91.
2007: Wang Zeneng; Nicholls Stephen J; Rodriguez E Rene; Kummu Outi; Hörkkö Sohvi; Barnard John; Reynolds Wanda F; Topol Eric J; DiDonato Joseph A; Hazen Stanley L
Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
Nature medicine 2007;13(10):1176-84.
2007: Wang Thomas H; Bhatt Deepak L; Fox Keith A A; Steinhubl Steven R; Brennan Danielle M; Hacke Werner; Mak Koon-Hou; Pearson Thomas A; Boden William E; Steg P Gabriel; Flather Marcus D; Montalescot Gilles; Topol Eric J;
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
European heart journal 2007;28(18):2200-7.
2007: Luke May M; Kane John P; Liu Dongming M; Rowland Charles M; Shiffman Dov; Cassano June; Catanese Joseph J; Pullinger Clive R; Leong Diane U; Arellano Andre R; Tong Carmen H; Movsesyan Irina; Naya-Vigne Josephina; Noordhof Curtis; Feric Nicole T; Malloy Mary J; Topol Eric J; Koschinsky Marlys L; Devlin James J; Ellis Stephen G
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(9):2030-6.
2007: Stenina Olga I; Topol Eric J; Plow Edward F
Thrombospondins, their polymorphisms, and cardiovascular disease.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(9):1886-94.
2007: Saw Jacqueline; Brennan Danielle M; Steinhubl Steven R; Bhatt Deepak L; Mak Koon-Hou; Fox Keith; Topol Eric J;
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Journal of the American College of Cardiology 2007;50(4):291-5.
2007: Mak Koon-Hou; Ma Stefan; Heng Derrick; Tan Chee-Eng; Tai E-Shyong; Topol Eric J; Chew Suok-Kai
Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events.
The American journal of cardiology 2007;100(2):227-33.
2007: Topol Eric J; Murray Sarah S; Frazer Kelly A
The genomics gold rush.
JAMA : the journal of the American Medical Association 2007;298(2):218-21.
2007: Brener Sorin J; Steinhubl Steven R; Berger Peter B; Brennan Danielle M; Topol Eric J;
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
The Journal of invasive cardiology 2007;19(7):287-90.
2007: Bhatt Deepak L; Chew Derek P; Grines Cindy; Mukherjee Debabrata; Leesar Massoud; Gilchrist Ian C; Corbelli John C; Blankenship James C; Eres Avichai; Steinhubl Steven; Tan Walter A; Resar Jon R; AlMahameed Amjad; Abdel-Latif Ahmed; Wilson Tang W H; Brennan Danielle; McErlean Ellen; Hazen Stanley L; Topol Eric J
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
American heart journal 2007;154(1):137-43.
2007: Bhatt Deepak L; Flather Marcus D; Hacke Werner; Berger Peter B; Black Henry R; Boden William E; Cacoub Patrice; Cohen Eric A; Creager Mark A; Easton J Donald; Hamm Christian W; Hankey Graeme J; Johnston S Claiborne; Mak Koon-Hou; Mas Jean-Louis; Montalescot Gilles; Pearson Thomas A; Steg P Gabriel; Steinhubl Steven R; Weber Michael A; Fabry-Ribaudo Liz; Hu Tingfei; Topol Eric J; Fox Keith A A;
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Journal of the American College of Cardiology 2007;49(19):1982-8.
2007: Topol Eric J; Frazer Kelly A
The resequencing imperative.
Nature genetics 2007;39(4):439-40.
2007: Topol Eric J
Stents and sensibility.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2007;69(4):616-7.
2007: Luo Albert K; Jefferson Brian K; Garcia Mario J; Ginsburg Geoffrey S; Topol Eric J
Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease.
Journal of medical genetics 2007;44(3):161-5.
2007: Shishehbor Mehdi H; Lauer Michael S; Singh Inder M; Chew Derek P; Karha Juhana; Brener Sorin J; Moliterno David J; Ellis Stephen G; Topol Eric J; Bhatt Deepak L
In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
Journal of the American College of Cardiology 2007;49(8):849-54.
2007: Mahaffey Kenneth W; Roe Matthew T; Kilaru Rakhi; Alexander John H; Van de Werf Frans; Califf Robert M; Simoons Maarten L; Topol Eric J; Harrington Robert A
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.
European heart journal 2007;28(4):425-32.
2007: Mehta Rajendra H; Califf Robert M; Garg Jyotsna; White Harvey D; Van de Werf Frans; Armstrong Paul W; Pieper Karen S; Topol Eric J; Granger Christopher B
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction.
European heart journal 2007;28(4):415-24.
2007: Anwaruddin Saif; Askari Arman T; Topol Eric J
Redefining risk in acute coronary syndromes using molecular medicine.
Journal of the American College of Cardiology 2007;49(3):279-89.
2007: Tang W H Wilson; Steinhubl Steven R; Van Lente Frederick; Brennan Danielle; McErlean Ellen; Maroo Anjli; Francis Gary S; Topol Eric J
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
American heart journal 2007;153(1):36-41.
2006: Ellis Stephen G; Penn Marc S; Bolwell Brian; Garcia Mario; Chacko Matthews; Wang Thomas; Brezina Kelly J; McConnell Gerry; Topol Eric J
Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial.
American heart journal 2006;152(6):1051.e9-14.
2006: Shishehbor Mehdi H; Zhang Renliang; Medina Hector; Brennan Marie-Luise; Brennan Danielle M; Ellis Stephen G; Topol Eric J; Hazen Stanley L
Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease.
Free radical biology & medicine 2006;41(11):1678-83.
2006: Saw Jacqueline; Bhatt Deepak L; Moliterno David J; Brener Sorin J; Steinhubl Steven R; Lincoff A Michael; Tcheng James E; Harrington Robert A; Simoons Maarten; Hu TingFei; Sheikh Mobeen A; Kereiakes Dean J; Topol Eric J
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
Journal of the American College of Cardiology 2006;48(8):1567-72.
2006: Nadeau Joseph H; Topol Eric J
The genetics of health.
Nature genetics 2006;38(10):1095-8.
2006: Topol Eric J; Smith Jonathan; Plow Edward F; Wang Qing K
Genetic susceptibility to myocardial infarction and coronary artery disease.
Human molecular genetics 2006;15 Spec No 2():R117-23.
2006: Smith Jonathan D; Topol Eric J
Identification of atherosclerosis-modifying genes: pathogenic insights and therapeutic potential.
Expert review of cardiovascular therapy 2006;4(5):703-9.
2006: Kao John; Lincoff A Michael; Topol Eric J; Madrid Antonio; J Price Matthew; Sawhney Neil; Teirstein Paul S
Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2006;68(3):352-6.
2006: Goodman Shaun G; Fu Yuling; Langer Anatoly; Barr Aiala; Tan Mary; Wagner Galen S; Barbagelata Alejandro; Sgarbossa Elena B; Birnbaum Yochai; Granger Christopher B; Califf Robert M; Van de Werf Frans; Topol Eric J; Armstrong Paul W;
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience.
American heart journal 2006;152(2):277-84.
2006: Salpeter Shelley R; Gregor Peter; Ormiston Thomas M; Whitlock Richard; Raina Parminder; Thabane Lehana; Topol Eric J
Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.
The American journal of medicine 2006;119(7):552-9.
2006: Exaire J Emilio; Butman Samuel M; Ebrahimi Ramin; Kleiman Neal S; Harrington Robert A; Schweiger Marc J; Bittl John A; Wolski Kathy; Topol Eric J; Lincoff A Michael;
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
American heart journal 2006;152(1):157-63.
2006: Rajagopal Vivek; Lincoff A Michael; Cohen David J; Gurm Hitinder S; Hu Tingfei; Desmet Walter J; Kleiman Neal S; Bittl John A; Feit Frederick; Topol Eric J
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
American heart journal 2006;152(1):149-54.
2006: Hewson Mariana G; Copeland H Liesel; Mascha Edward; Arrigain Susana; Topol Eric; Fox Joan E B
Integrative medicine: implementation and evaluation of a professional development program using experiential learning and conceptual change teaching approaches.
Patient education and counseling 2006;62(1):5-12.
2006: Shiffman Dov; Rowland Charles M; Louie Judy Z; Luke May M; Bare Lance A; Bolonick Joel I; Young Bradford A; Catanese Joseph J; Stiggins Charles F; Pullinger Clive R; Topol Eric J; Malloy Mary J; Kane John P; Ellis Stephen G; Devlin James J
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(7):1613-8.
2006: Chew D P; Bhatt D L; Lincoff A M; Wolski K; Topol E J
Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk.
Heart (British Cardiac Society) 2006;92(7):945-50.
2006: Robertson Jason O; Lincoff A Michael; Wolski Kathy; Topol Eric J
Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
The American journal of cardiology 2006;97(12):1679-84.
2006: Blankenship James C; Haldis Tom; Feit Frederick; Hu Tingfei; Kleiman Neal S; Topol Eric J; Lincoff A Michael;
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy).
The American journal of cardiology 2006;97(11):1591-6.
2006: Shishehbor Mehdi H; Topol Eric J; Mukherjee Debabrata; Hu Tingfei; Cohen David J; Stone Gregg W; McClure Rick; Roffi Marco; Moliterno David J;
Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
The American journal of cardiology 2006;97(11):1585-90.
2006: Topol Eric J
The genetics of heart attack.
Heart (British Cardiac Society) 2006;92(6):855-61.
2006: Bushnell Cheryl D; Griffin Jeffrey; Newby L Kristin; Goldstein Larry B; Mahaffey Kenneth W; Graffagnino Carmelo A; Harrington Robert A; White Harvey D; Simes R John; Califf Robert M; Topol Eric J; Easton J Donald
Statin use and sex-specific stroke outcomes in patients with vascular disease.
Stroke; a journal of cerebral circulation 2006;37(6):1427-31.
2006: Chacko Matthews; Lincoff A Michael; Wolski Katherine E; Cohen David J; Bittl John A; Lansky Alexandra J; Tsuchiya Yoshihiro; Betriu Amadeo; Yen Michael H; Chew Derek P; Cho Leslie; Topol Eric J
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
American heart journal 2006;151(5):1032.e1-7.
2006: Schoenhagen Paul; Stillman Arthur E; Garcia Mario J; Halliburton Sandra S; Tuzcu E Murat; Nissen Steven E; Modic Michael T; Lytle Bruce W; Topol Eric J; White Richard D
Coronary artery imaging with multidetector computed tomography: a call for an evidence-based, multidisciplinary approach.
American heart journal 2006;151(5):945-8.
2006: Martin Jack L; Jia Gang; Martin Seth S; Shapiro Timothy A; Herrmann Howard C; Dibattiste Peter M; Topol Eric J; Moliterno David J
The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2006;67(4):563-70.
2006: Bhatt Deepak L; Fox Keith A A; Hacke Werner; Berger Peter B; Black Henry R; Boden William E; Cacoub Patrice; Cohen Eric A; Creager Mark A; Easton J Donald; Flather Marcus D; Haffner Steven M; Hamm Christian W; Hankey Graeme J; Johnston S Claiborne; Mak Koon-Hou; Mas Jean-Louis; Montalescot Gilles; Pearson Thomas A; Steg P Gabriel; Steinhubl Steven R; Weber Michael A; Brennan Danielle M; Fabry-Ribaudo Liz; Booth Joan; Topol Eric J;
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
The New England journal of medicine 2006;354(16):1706-17.
2006: Wang Kai; Zhou Zhongmin; Zhang Ming; Fan Liming; Forudi Farhad; Zhou Xiaorong; Qu Wu; Lincoff A Michael; Schmidt Ann Marie; Topol Eric J; Penn Marc S
Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
The Journal of pharmacology and experimental therapeutics 2006;317(1):37-43.
2006: Kelly Robert V; Hsu Amy; Topol Eric; Steinhubl Steven
The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention.
The Journal of invasive cardiology 2006;18(3):115-9.
2006: Steinhubl Steven R; Berger Peter B; Brennan Danielle M; Topol Eric J;
Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention.
Journal of the American College of Cardiology 2006;47(5):939-43.
2006: Wang Thomas H; Bhatt Deepak L; Topol Eric J
Aspirin and clopidogrel resistance: an emerging clinical entity.
European heart journal 2006;27(6):647-54.
2006: De Luca Giuseppe; Suryapranata Harry; Stone Gregg W; Antoniucci David; Tcheng James E; Neumann Franz-Josef; Bonizzoni Erminio; Topol Eric J; Chiariello Massimo
Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
Journal of the American College of Cardiology 2006;47(3):685-6.
2006: Brener Sorin J; Lytle Bruce W; Casserly Ivan P; Ellis Stephen G; Topol Eric J; Lauer Michael S
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery.
European heart journal 2006;27(4):413-8.
2006: Mehta Rajendra H; Marks David; Califf Robert M; Sohn SeeHyang; Pieper Karen S; Van de Werf Frans; Peterson Eric D; Ohman E Magnus; White Harvey D; Topol Eric J; Granger Christopher B
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction.
The American journal of medicine 2006;119(1):70.e1-8.
2006: Karha Juhana; Topol Eric J
Primary percutaneous coronary intervention vs. fibrinolytic therapy for acute ST-elevation myocardial infarction in the elderly.
The American journal of geriatric cardiology 2006;15(1):19-21.
2006: Galla John M; Mahaffey Kenneth W; Sapp Shelly K; Alexander John H; Roe Matthew T; Ohman E Magnus; Granger Christopher B; Armstrong Paul W; Harrington Robert A; White Harvey D; Simoons Maarten L; Newby L Kristin; Califf Robert M; Topol Eric J
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
American heart journal 2006;151(1):16-24.
2006: Helgadottir Anna; Manolescu Andrei; Helgason Agnar; Thorleifsson Gudmar; Thorsteinsdottir Unnur; Gudbjartsson Daniel F; Gretarsdottir Solveig; Magnusson Kristinn P; Gudmundsson Gudmundur; Hicks Andrew; Jonsson Thorlakur; Grant Struan F A; Sainz Jesus; O'Brien Stephen J; Sveinbjornsdottir Sigurlaug; Valdimarsson Einar M; Matthiasson Stefan E; Levey Allan I; Abramson Jerome L; Reilly Murdach P; Vaccarino Viola; Wolfe Megan L; Gudnason Vilmundur; Quyyumi Arshed A; Topol Eric J; Rader Daniel J; Thorgeirsson Gudmundur; Gulcher Jeffrey R; Hakonarson Hakon; Kong Augustine; Stefansson Kari
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction.
Nature genetics 2006;38(1):68-74.
2006: Mukherjee D; Topol E J; Moliterno D J; Brennan D M; Ziada K; Cho L; Steinhubl S R;
Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment.
Heart (British Cardiac Society) 2006;92(1):49-51.
2005: Ebrahimi Ramin; Lincoff A Michael; Bittl John A; Chew Derek; Wolski Kathy; Wadhan Nitin; Toggart Edward J; Topol Eric J
Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis.
Journal of cardiovascular pharmacology and therapeutics 2005;10(4):209-16.
2005: Mukherjee Debabrata; Topol Eric J; Bertrand Michel E; Kristensen Steen D; Herrmann Howard C; Neumann Franz-Josef; Yakubov Steven J; Bassand Jean-Pierre; McClure Rick R; Stone Gregg W; Ardissino Diego; Moliterno David J;
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
European heart journal 2005;26(23):2524-8.
2005: Pluskota Elzbieta; Stenina Olga I; Krukovets Irene; Szpak Dorota; Topol Eric J; Plow Edward F
Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function.
Blood 2005;106(12):3970-8.
2005: Vasilyev Nikolay; Williams Timothy; Brennan Marie-Luise; Unzek Samuel; Zhou Xiaorong; Heinecke Jay W; Spitz Douglas R; Topol Eric J; Hazen Stanley L; Penn Marc S
Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction.
Circulation 2005;112(18):2812-20.
2005: Nissen Steven E; Wolski Kathy; Topol Eric J
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
JAMA : the journal of the American Medical Association 2005;294(20):2581-6.
2005: Sinnaeve Peter R; Simes John; Yusuf Salim; Garg Jyotsna; Mehta Shamir; Eikelboom John; Bittl John A; Serruys Patrick; Topol Eric J; Granger Christopher B
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention.
European heart journal 2005;26(22):2396-403.
2005: Stenina Olga I; Ustinov Valentin; Krukovets Irene; Marinic Tina; Topol Eric J; Plow Edward F
Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(13):1893-5.
2005: Topol Eric J
Simon Dack Lecture. The genomic basis of myocardial infarction.
Journal of the American College of Cardiology 2005;46(8):1456-65.
2005: Shiffman Dov; Ellis Stephen G; Rowland Charles M; Malloy Mary J; Luke May M; Iakoubova Olga A; Pullinger Clive R; Cassano June; Aouizerat Bradley E; Fenwick Raymond G; Reitz Richard E; Catanese Joseph J; Leong Diane U; Zellner Christian; Sninsky John J; Topol Eric J; Devlin James J; Kane John P
Identification of four gene variants associated with myocardial infarction.
American journal of human genetics 2005;77(4):596-605.
2005: Savonitto Stefano; Cohen Mauricio G; Politi Alessandro; Hudson Michael P; Kong David F; Huang Yao; Pieper Karen S; Mauri Francesco; Wagner Galen S; Califf Robert M; Topol Eric J; Granger Christopher B
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes.
European heart journal 2005;26(20):2106-13.
2005: Agah Ramtin; Ellis Stephen; Chase Sue; Henderson Mark; Mlady Lisa; Murugesan Gurunathan; Tubbs Raymond; Marchant Kandice; Warshawsky Ilka; Rouse Colleen; Hughes Kathy; Welch Patricia; Topol Eric J
Creation of a large-scale genetic data bank for cardiovascular association studies.
American heart journal 2005;150(3):500-6.
2005: Bhatt Deepak L; Fox Keith A; Hacke Werner; Berger Peter B; Black Henry R; Boden William E; Cacoub Patrice; Cohen Eric A; Creager Mark A; Easton J Donald; Flather Marcus D; Haffner Steven M; Hamm Christian W; Hankey Graeme J; Johnston S Claiborne; Mak Koon-Hou; Mas Jean-Louis; Montalescot Gilles; Pearson Thomas A; Steg P Gabriel; Steinhubl Steven R; Weber Michael A; Booth Joan; Topol Eric J;
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
American heart journal 2005;150(3):401.
2005: Chen Michael S; Bhatt Deepak L; Chew Derek P; Moliterno David J; Ellis Stephen G; Topol Eric J
Outcomes in African Americans and whites after percutaneous coronary intervention.
The American journal of medicine 2005;118(9):1019-25.
2005: Beinart Sean C; Kolm Paul; Veledar Emir; Zhang Zefeng; Mahoney Elizabeth M; Bouin Olivier; Gabriel Sylvie; Jackson Joseph; Chen Roland; Caro Jaime; Steinhubl Steven; Topol Eric; Weintraub William S
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Journal of the American College of Cardiology 2005;46(5):761-9.
2005: Bhatt Deepak L; Topol Eric J
Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes.
Circulation 2005;112(6):906-15; discussion 923.
2005: Wang Kai; Zhou Xiaorong; Zhou Zhongmin; Mal Niladri; Fan Liming; Zhang Ming; Lincoff A Michael; Plow Edward F; Topol Eric J; Penn Marc S
Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(8):1584-9.
2005: Nallamothu Brahmajee K; Bates Eric R; Hochman Judith S; Granger Christopher B; Guetta Victor; Wilcox Robert G; White Harvey D; Armstrong Paul W; Savonitto Stefano; Jia Gang; Lincoff A Michael; Topol Eric J;
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.
European heart journal 2005;26(15):1506-12.
2005: Brener Sorin J; Lincoff A Michael; Bates Eric R; Jia Gang; Armstrong Paul W; Guetta Victor; Hochman Judith S; Savonitto Stefano; Wilcox Robert G; White Harvey D; Topol Eric J;
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.
American heart journal 2005;150(1):89-93.
2005: Topol Eric J
Nesiritide - not verified.
The New England journal of medicine 2005;353(2):113-6.
2005: Jefferson Brian K; Topol Eric J
Molecular mechanisms of myocardial infarction.
Current problems in cardiology 2005;30(7):333-74.
2005: Gurm H S; Topol E J
The ECG in acute coronary syndromes: new tricks from an old dog.
Heart (British Cardiac Society) 2005;91(7):851-3.
2005: Narizhneva Natalya V; Razorenova Olga V; Podrez Eugene A; Chen Juhua; Chandrasekharan Unni M; DiCorleto Paul E; Plow Edward F; Topol Eric J; Byzova Tatiana V
Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(9):1158-60.
2005: Gurm Hitinder S; Sarembock Ian J; Kereiakes Dean J; Young John J; Harrington Robert A; Kleiman Neal; Feit Frederick; Wolski Kathy; Bittl John A; Wilcox Robert; Topol Eric J; Lincoff A Michael
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Journal of the American College of Cardiology 2005;45(12):1932-8.
2005: Mahaffey Kenneth W; Roe Matthew T; Kilaru Rakhi; French John K; Alexander John H; Berdan Lisa G; Van De Werf Frans; Simoons Maarten L; Weaver W Douglas; White Harvey D; Lincoff A Michael; Kleiman Neal S; Topol Eric J; Harrington Robert A
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
The American journal of cardiology 2005;95(12):1404-8.
2005: Wang Qing; Rao Shaoqi; Topol Eric J
Miscues on the "lack of MEF2A mutations" in coronary artery disease.
The Journal of clinical investigation 2005;115(6):1399-400; author reply 1400-1.
2005: Topol Eric J; Blumenthal David
Physicians and the investment industry.
JAMA : the journal of the American Medical Association 2005;293(21):2654-7.
2005: Mehta Rajendra H; Califf Robert M; Garg Jyotsna; Pieper Karen S; Alexander John H; Moliterno David J; Van de Werf Frans; Ohman E Magnus; White Harvey D; Topol Eric J; Granger Christopher B
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy.
The American journal of cardiology 2005;95(11):1371-5.
2005: Berger Peter B; Best Patricia J M; Topol Eric J; White Jennifer; DiBattiste Peter M; Chan Albert W; Kristensen Steen D; Herrmann Howard C; Moliterno David J
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
American heart journal 2005;149(5):869-75.
2005: Hakonarson Hakon; Thorvaldsson Sverrir; Helgadottir Anna; Gudbjartsson Daniel; Zink Florian; Andresdottir Margret; Manolescu Andrei; Arnar David O; Andersen Karl; Sigurdsson Axel; Thorgeirsson Gestur; Jonsson Asgeir; Agnarsson Uggi; Bjornsdottir Halldora; Gottskalksson Gizur; Einarsson Atli; Gudmundsdottir Hrefna; Adalsteinsdottir Asdis E; Gudmundsson Kolbeinn; Kristjansson Kristleifur; Hardarson Thordur; Kristinsson Arni; Topol Eric J; Gulcher Jeffrey; Kong Augustine; Gurney Mark; Thorgeirsson Gudmundur; Stefansson Kari
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
JAMA : the journal of the American Medical Association 2005;293(18):2245-56.
2005: Serebruany Victor L; Steinhubl Steven R; Berger Peter B; Malinin Alex I; Baggish Jeffrey S; Bhatt Deepak L; Topol Eric J
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
The American journal of cardiology 2005;95(10):1218-22.
2005: Topol Eric J
A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.
American heart journal 2005;149(4 Suppl):S100-6.
2005: Meine Trip J; Al-Khatib Sana M; Alexander John H; Granger Christopher B; White Harvey D; Kilaru Rakhi; Williams Kathryn; Ohman E Magnus; Topol Eric; Califf Robert M
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.
American heart journal 2005;149(4):670-4.
2005: De Luca Giuseppe; Suryapranata Harry; Stone Gregg W; Antoniucci David; Tcheng James E; Neumann Franz-Josef; Van de Werf Frans; Antman Elliott M; Topol Eric J
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
JAMA : the journal of the American Medical Association 2005;293(14):1759-65.
2005: Jefferson Brian K; Foster Jennifer H; McCarthy Jeanette J; Ginsburg Geoffrey; Parker Alex; Kottke-Marchant Kandice; Topol Eric J
Aspirin resistance and a single gene.
The American journal of cardiology 2005;95(6):805-8.
2005: Chan Albert W; Yadav Jay S; Bhatt Deepak L; Bajzer Christopher T; Gum Patricia A; Roffi Marco; Cho Leslie; Agah Ramtin; Topol Eric J
Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting.
The American journal of cardiology 2005;95(6):791-5.
2005: Gurm Hitinder S; Rajagopal Vivek; Fathi Robert; Vivekanathan Deepak; Yadav Jay S; Bhatt Deepak L; Ellis Stephen G; Lincoff A Michael; Topol Eric J
Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
The American journal of cardiology 2005;95(6):716-21.
2005: Rebeiz Abdallah G; Johanson Per; Green Cindy L; Crater Suzanne W; Roe Matthew T; Langer Anatoly; Giugliano Robert P; Lincoff A Michael; Newby L Kristin; Harrington Robert A; Topol Eric J; Califf Robert M; Wagner Galen S; Krucoff Mitchell W
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
The American journal of cardiology 2005;95(5):611-4.
2005: Chew Derek P; Lincoff A Michael; Gurm Hitinder; Wolski Katherine; Cohen David J; Henry Tim; Feit Frederick; Topol Eric J;
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
The American journal of cardiology 2005;95(5):581-5.
2005: Topol Eric J
Cholesterol, racial variation and targeted medicines.
Nature medicine 2005;11(2):122-3.
2005: Serebruany Victor L; Steinhubl Steven R; Berger Peter B; Malinin Alex I; Bhatt Deepak L; Topol Eric J
Variability in platelet responsiveness to clopidogrel among 544 individuals.
Journal of the American College of Cardiology 2005;45(2):246-51.
2005: Topol Eric J
Arthritis medicines and cardiovascular events--"house of coxibs".
JAMA : the journal of the American Medical Association 2005;293(3):366-8.
2005: Labinaz Marino; Mathias Jasmine; Pieper Karen; Granger Christopher B; Lincoff A Michael; Moliterno David J; Van de Werf Frans; Simes John; White Harvey D; Simoons Maarten L; Califf Robert M; Topol Eric J; Armstrong Paul W; Harrington Robert A
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
European heart journal 2005;26(2):128-36.
2005: Wang Kai; Tarakji Khaldoun; Zhou Zhongmin; Zhang Ming; Forudi Farhad; Zhou Xiaorong; Koki Alane T; Smith Mark E; Keller Bradley T; Topol Eric J; Lincoff A Michael; Penn Marc S
Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.
Journal of cardiovascular pharmacology 2005;45(1):61-7.
2005: Li Li; Jiang Wei; Li Xia; Moser Kathy L; Guo Zheng; Du Lei; Wang Qiuju; Topol Eric J; Wang Qing; Rao Shaoqi
A robust hybrid between genetic algorithm and support vector machine for extracting an optimal feature gene subset.
Genomics 2005;85(1):16-23.
2005: Eikelboom John; Feldman Mark; Mehta Shamir R; Michelson Alan D; Oates John A; Topol Eric
Aspirin resistance and its implications in clinical practice.
MedGenMed : Medscape general medicine 2005;7(3):76.
2005: Guo Zheng; Zhang Tianwen; Li Xia; Wang Qi; Xu Jianzhen; Yu Hui; Zhu Jing; Wang Haiyun; Wang Chenguang; Topol Eric J; Wang Qing; Rao Shaoqi
Towards precise classification of cancers based on robust gene functional expression profiles.
BMC bioinformatics 2005;6():58.
2004: Karha Juhana; Topol Eric J
The sad story of Vioxx, and what we should learn from it.
Cleveland Clinic journal of medicine 2004;71(12):933-4, 936, 938-9.
2004: Chiu John H; Bhatt Deepak L; Ziada Khaled M; Chew Derek P; Whitlow Patrick L; Lincoff A Michael; Ellis Stephen G; Topol Eric J
Impact of female sex on outcome after percutaneous coronary intervention.
American heart journal 2004;148(6):998-1002.
2004: Steinhubl Steven R; Topol Eric J
Risk reduction with long-term clopidogrel following percutaneous coronary intervention.
European heart journal 2004;25(23):2169-70; author reply 2170-1.
2004: Bhagavatula M R Krishna; Fan Chun; Shen Gong-Qing; Cassano June; Plow Edward F; Topol Eric J; Wang Qing
Transcription factor MEF2A mutations in patients with coronary artery disease.
Human molecular genetics 2004;13(24):3181-8.
2004: Maroo A; Topol E J
The early history and development of thrombolysis in acute myocardial infarction.
Journal of thrombosis and haemostasis : JTH 2004;2(11):1867-70.
2004: Nissen Steven E; Tuzcu E Murat; Libby Peter; Thompson Paul D; Ghali Magdi; Garza Dahlia; Berman Lance; Shi Harry; Buebendorf Ethel; Topol Eric J;
Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2004;292(18):2217-25.
2004: Cohen David J; Lincoff A Michael; Lavelle Tara A; Chen Huei-Ling; Bakhai Ameet; Berezin Ronna H; Jackman Daniel; Sarembock Ian J; Topol Eric J
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Journal of the American College of Cardiology 2004;44(9):1792-800.
2004: Li Xia; Rao Shaoqi; Zhang Tianwen; Guo Zheng; Zhang Qingpu; Moser Kathy L; Topol Eric J
An ensemble method for gene discovery based on DNA microarray data.
Science in China. Series C, Life sciences / Chinese Academy of Sciences 2004;47(5):396-405.
2004: Topol Eric J
Failing the public health--rofecoxib, Merck, and the FDA.
The New England journal of medicine 2004;351(17):1707-9.
2004: Rao Sunil V; Jollis James G; Harrington Robert A; Granger Christopher B; Newby L Kristin; Armstrong Paul W; Moliterno David J; Lindblad Lauren; Pieper Karen; Topol Eric J; Stamler Jonathan S; Califf Robert M
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.
JAMA : the journal of the American Medical Association 2004;292(13):1555-62.
2004: Cura Fernando A; Roffi Marco; Pasca Narcis; Wolski Katherine E; Lincoff A Michael; Topol Eric J; Lauer Michael S;
ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
The American journal of cardiology 2004;94(7):859-63.
2004: Ellis Stephen G; Bajzer Christopher T; Bhatt Deepak L; Brener Sorin J; Whitlow Patrick L; Lincoff A Michael; Moliterno David J; Raymond Russell E; Tuzcu E Murat; Franco Irving; Dushman-Ellis Sandra; Lander Katherine J; Schneider Jakob P; Topol Eric J
Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2004;63(2):135-40.
2004: Kaul Padma; Armstrong Paul W; Chang Wei-Ching; Naylor C David; Granger Christopher B; Lee Kerry L; Peterson Eric D; Califf Robert M; Topol Eric J; Mark Daniel B
Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
Circulation 2004;110(13):1754-60.
2004: Asher Craig R; Moliterno David J; Bhapkar Manjushri V; McGuire Darren K; Rao Sunil V; Holmes David R; Newby L Kristin; Bates Eric R; Topol Eric J;
Association of race with complications and prognosis following acute coronary syndromes.
The American journal of cardiology 2004;94(6):792-4.
2004: Saw Jacqueline; Lincoff A Michael; DeSmet Walter; Betriu Amadeo; Rutsch Wolfgang; Wilcox Robert G; Kleiman Neil S; Wolski Kathy; Topol Eric J;
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Journal of the American College of Cardiology 2004;44(6):1194-9.
2004: Topol Eric J
Invisible showers.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2004;63(1):42-3.
2004: Saw Jacqueline; Topol Eric J; Steinhubl Steven R; Brennan Danielle; Berger Peter B; Moliterno David J;
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention.
The American journal of cardiology 2004;94(5):623-5.
2004: Topol Eric J; Falk Gary W
A coxib a day won't keep the doctor away.
Lancet 2004;364(9435):639-40.
2004: Bhatt Deepak L; Topol Eric J;
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
American heart journal 2004;148(2):263-8.
2004: Lincoff A Michael; Kleiman Neal S; Kereiakes Dean J; Feit Frederick; Bittl John A; Jackman J Daniel; Sarembock Ian J; Cohen David J; Spriggs Douglas; Ebrahimi Ramin; Keren Gadi; Carr Jeffrey; Cohen Eric A; Betriu Amadeo; Desmet Walter; Rutsch Wolfgang; Wilcox Robert G; de Feyter Pim J; Vahanian Alec; Topol Eric J;
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
JAMA : the journal of the American Medical Association 2004;292(6):696-703.
2004: Brener Sorin J; Moliterno David J; Lincoff A Michael; Steinhubl Steven R; Wolski Kathy E; Topol Eric J
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Circulation 2004;110(8):994-8.
2004: Vivekananthan Deepak P; Bhatt Deepak L; Chew Derek P; Zidar Frank J; Chan Albert W; Moliterno David J; Ellis Stephen G; Topol Eric J
Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.
The American journal of cardiology 2004;94(3):358-60.
2004: Rajagopal Vivek; Gurm Hitinder S; Bhatt Deepak L; Lincoff A Michael; Tcheng James E; Kereiakes Dean J; Kleiman Neal S; Jia Gang; Topol Eric J
Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.
The American journal of cardiology 2004;94(2):190-2.
2004: Gurm Hitinder S; Lincoff A Michael; Kleiman Neil S; Kereiakes Dean J; Tcheng James E; Aronow Herbert D; Askari Arman T; Brennan Danielle M; Topol Eric J
Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.
The American journal of cardiology 2004;94(1):30-4.
2004: Penn Marc S; Zhang Ming; Deglurkar Indu; Topol Eric J
Role of stem cell homing in myocardial regeneration.
International journal of cardiology 2004;95 Suppl 1():S23-5.
2004: Stenina Olga I; Byzova Tatiana V; Adams Josephine C; McCarthy Jeanette J; Topol Eric J; Plow Edward F
Coronary artery disease and the thrombospondin single nucleotide polymorphisms.
The international journal of biochemistry & cell biology 2004;36(6):1013-30.
2004: Askari Arman; Unzek Samuel; Goldman Corey K; Ellis Stephen G; Thomas James D; DiCorleto Paul E; Topol Eric J; Penn Marc S
Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy.
Journal of the American College of Cardiology 2004;43(10):1908-14.
2004: Wessel Jennifer; Topol Eric J; Ji Ming; Meyer Joanne; McCarthy Jeanette J
Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction.
American heart journal 2004;147(5):905-9.
2004: McCarthy J J; Parker A; Salem R; Moliterno D J; Wang Q; Plow E F; Rao S; Shen G; Rogers W J; Newby L K; Cannata R; Glatt K; Topol E J;
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes.
Journal of medical genetics 2004;41(5):334-41.
2004: Brener Sorin J; Lytle Bruce W; Casserly Ivan P; Schneider Jakob P; Topol Eric J; Lauer Michael S
Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features.
Circulation 2004;109(19):2290-5.
2004: Merlini Piera Angelica; Rossi Marco; Menozzi Alberto; Buratti Silvia; Brennan Danielle M; Moliterno David J; Topol Eric J; Ardissino Diego
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Circulation 2004;109(18):2203-6.
2004: Lincoff A Michael; Bittl John A; Kleiman Neal S; Sarembock Ian J; Jackman J Daniel; Mehta Sameer; Tannenbaum Mark A; Niederman Alan L; Bachinsky William B; Tift-Mann J; Parker H Graham; Kereiakes Dean J; Harrington Robert A; Feit Frederick; Maierson Elizabeth S; Chew Derek P; Topol Eric J;
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
The American journal of cardiology 2004;93(9):1092-6.
2004: Narizhneva Natalya V; Byers-Ward Vicky J; Quinn Martin J; Zidar Frank J; Plow Edward F; Topol Eric J; Byzova Tatiana V
Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction.
The Journal of biological chemistry 2004;279(20):21651-7.
2004: Ellis Stephen G; Armstrong Paul; Betriu Amadeo; Brodie Bruce; Herrmann Howard; Montalescot Gilles; Neumann Franz-Josef; Smith John J; Topol Eric;
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
American heart journal 2004;147(4):E16.
2004: Casserly Ivan; Topol Eric
Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.
Lancet 2004;363(9415):1139-46.
2004: Freedman Matthew L; Reich David; Penney Kathryn L; McDonald Gavin J; Mignault Andre A; Patterson Nick; Gabriel Stacey B; Topol Eric J; Smoller Jordan W; Pato Carlos N; Pato Michele T; Petryshen Tracey L; Kolonel Laurence N; Lander Eric S; Sklar Pamela; Henderson Brian; Hirschhorn Joel N; Altshuler David
Assessing the impact of population stratification on genetic association studies.
Nature genetics 2004;36(4):388-93.
2004: Topol Eric J
Intensive statin therapy--a sea change in cardiovascular prevention.
The New England journal of medicine 2004;350(15):1562-4.
2004: Quinn Martin J; Aronow Herbert D; Califf Robert M; Bhatt Deepak L; Sapp Shelly; Kleiman Neal S; Harrington Robert A; Kong David F; Kandzari David E; Topol Eric J
Aspirin dose and six-month outcome after an acute coronary syndrome.
Journal of the American College of Cardiology 2004;43(6):972-8.
2004: Bittl John A; Chew Derek P; Topol Eric J; Kong David F; Califf Robert M
Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty.
Journal of the American College of Cardiology 2004;43(6):936-42.
2004: Quinn Martin J; Bhatt Deepak L; Zidar Frank; Vivekananthan Deepak; Chew Derek P; Ellis Stephen G; Plow Edward; Topol Eric J
Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.
The American journal of cardiology 2004;93(6):679-84.
2004: Saw Jacqueline; Topol Eric J
Lack of adverse clopidogrel-atorvastatin clinical interaction.
The American journal of cardiology 2004;93(5):669; author reply 669-70.
2004: Helgadottir Anna; Manolescu Andrei; Thorleifsson Gudmar; Gretarsdottir Solveig; Jonsdottir Helga; Thorsteinsdottir Unnur; Samani Nilesh J; Gudmundsson Gudmundur; Grant Struan F A; Thorgeirsson Gudmundur; Sveinbjornsdottir Sigurlaug; Valdimarsson Einar M; Matthiasson Stefan E; Johannsson Halldor; Gudmundsdottir Olof; Gurney Mark E; Sainz Jesus; Thorhallsdottir Margret; Andresdottir Margret; Frigge Michael L; Topol Eric J; Kong Augustine; Gudnason Vilmundur; Hakonarson Hakon; Gulcher Jeffrey R; Stefansson Kari
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.
Nature genetics 2004;36(3):233-9.
2004: Roe M T; Mahaffey K W; Kilaru R; Alexander J H; Akkerhuis K M; Simoons M L; Harrington R A; Tardiff B E; Granger C B; Ohman E M; Moliterno D J; Lincoff A M; Armstrong P W; Van de Werf F; Califf R M; Topol E J
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
European heart journal 2004;25(4):313-21.
2004: Kaul Padma; Newby L Kristin; Fu Yuling; Mark Daniel B; Califf Robert M; Topol Eric J; Aylward Phil; Granger Christopher B; Van de Werf Frans; Armstrong Paul W
International differences in evolution of early discharge after acute myocardial infarction.
Lancet 2004;363(9408):511-7.
2004: Gurm Hitinder S; Lincoff A Michael; Lee David; Tang W H Wilson; Jia Gang; Booth Joan E; Califf Robert M; Ohman E M; Van de Werf Frans; Armstrong Paul W; Guetta Victor; Wilcox Robert; Topol Eric J;
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
Journal of the American College of Cardiology 2004;43(4):542-8.
2004: Roffi Marco; Topol Eric J
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
European heart journal 2004;25(3):190-8.
2004: Kandzari David E; Granger Christopher B; Simoons Maarten L; White Harvey D; Simes John; Mahaffey Kenneth W; Gore Joel; Weaver W Douglas; Longstreth William T; Stebbins Amanda; Lee Kerry L; Califf Robert M; Topol Eric J;
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
The American journal of cardiology 2004;93(4):458-61.
2004: McGuire Darren K; Newby L Kristin; Bhapkar Manjushri V; Moliterno David J; Hochman Judith S; Klein Werner W; Weaver W Douglas; Pfisterer Matthias; Corbalán Ramón; Dellborg Mikael; Granger Christopher B; Van De Werf Frans; Topol Eric J; Califf Robert M;
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
American heart journal 2004;147(2):246-52.
2004: Lee David S; Bhatt Deepak L; Moliterno David J; Peacock W Frank; Ellis Stephen G; Topol Eric J
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
The Journal of invasive cardiology 2004;16(2):46-51.
2004: Ringleb Peter A; Bhatt Deepak L; Hirsch Alan T; Topol Eric J; Hacke Werner;
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Stroke; a journal of cerebral circulation 2004;35(2):528-32.
2004: Wang Qing; Rao Shaoqi; Shen Gong-Qing; Li Lin; Moliterno David J; Newby L Kristin; Rogers William J; Cannata Ruth; Zirzow Erich; Elston Robert C; Topol Eric J
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis.
American journal of human genetics 2004;74(2):262-71.
2004: Exaire Jose E; Dauerman Harold L; Topol Eric J; Blankenship James C; Wolski Kathy; Raymond Russell E; Cohen Eric A; Moliterno David J;
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
American heart journal 2004;147(1):31-4.
2004: Watson Karol E; Topol Eric J
Pathobiology of atherosclerosis: are there racial and ethnic differences?
Reviews in cardiovascular medicine 2004;5 Suppl 3():S14-21.
2004: Brener Sorin J; Topol Eric J
Adjunctive therapy for percutaneous revascularization in acute myocardial infarction.
Current pharmaceutical design 2004;10(4):399-405.
2003: Brener Sorin J; Bhatt Deepak L; Moliterno David J; Schneider Jakob P; Ellis Stephen G; Topol Eric J
Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation.
The American journal of cardiology 2003;92(12):1468-71.
2003: Mukherjee Debabrata; Hsu Amy; Moliterno David J; Lincoff A Michael; Goormastic Marlene; Topol Eric J
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old.
The American journal of cardiology 2003;92(12):1465-7.
2003: Topol Eric J; Neumann Franz Josef; Montalescot Gilles
A preferred reperfusion strategy for acute myocardial infarction.
Journal of the American College of Cardiology 2003;42(11):1886-9.
2003: Kramer Judith M; Newby L Kristin; Chang Wei Ching; Simes R John; Van de Werf Frans; Granger Christopher B; Lee Kerry L; White Harvey D; Piegas Leopoldo S; Topol Eric J; Califf Robert M; Armstrong Paul W;
International variation in the use of evidence-based medicines for acute coronary syndromes.
European heart journal 2003;24(23):2133-41.
2003: McCarthy Jeanette J; Meyer Joanne; Moliterno David J; Newby L Kristin; Rogers William J; Topol Eric J;
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients.
Human genetics 2003;114(1):87-98.
2003: Topol Eric J; Lauer Michael S
The rudimentary phase of personalised medicine: coronary risk scores.
Lancet 2003;362(9398):1776-7.
2003: Wang Lejin; Fan Chun; Topol Sarah E; Topol Eric J; Wang Qing
Mutation of MEF2A in an inherited disorder with features of coronary artery disease.
Science (New York, N.Y.) 2003;302(5650):1578-81.
2003: Aronow Herbert D; Novaro Gian M; Lauer Michael S; Brennan Danielle M; Lincoff A Michael; Topol Eric J; Kereiakes Dean J; Nissen Steven E
In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis.
Archives of internal medicine 2003;163(21):2576-82.
2003: Topol Eric J
Current status and future prospects for acute myocardial infarction therapy.
Circulation 2003;108(16 Suppl 1):III6-13.
2003: Brennan Marie-Luise; Penn Marc S; Van Lente Frederick; Nambi Vijay; Shishehbor Mehdi H; Aviles Ronnier J; Goormastic Marlene; Pepoy Michael L; McErlean Ellen S; Topol Eric J; Nissen Steven E; Hazen Stanley L
Prognostic value of myeloperoxidase in patients with chest pain.
The New England journal of medicine 2003;349(17):1595-604.
2003: Khot Umesh N; Jia Gang; Moliterno David J; Lincoff A Michael; Khot Monica B; Harrington Robert A; Topol Eric J
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.
JAMA : the journal of the American Medical Association 2003;290(16):2174-81.
2003: Gurm Hitinder S; Bhatt Deepak L; Gupta Ritesh; Ellis Stephen G; Topol Eric J; Lauer Michael S
Preprocedural white blood cell count and death after percutaneous coronary intervention.
American heart journal 2003;146(4):692-8.
2003: Mukherjee Debabrata; Topol Eric J
Pharmaceutical advertising versus research spending: are profits more important than patients?
American heart journal 2003;146(4):563-4.
2003: Savonitto S; Armstrong P W; Lincoff A M; Jia G; Sila C A; Booth J; Terrosu P; Cavallini C; White H D; Ardissino D; Califf R M; Topol E J
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial.
European heart journal 2003;24(20):1807-14.
2003: Topol Eric J;
Anticoagulation with prosthetic cardiac valves.
Archives of internal medicine 2003;163(18):2251-2.
2003: Chan Albert W; Moliterno David J; Berger Peter B; Stone Gregg W; DiBattiste Peter M; Yakubov Steven L; Sapp Shelly K; Wolski Kathy; Bhatt Deepak L; Topol Eric J;
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Journal of the American College of Cardiology 2003;42(7):1188-95.
2003: Migrino Raymond Q; Topol Eric J;
A matter of life and death? The Heart Protection Study and protection of clinical trial participants.
Controlled clinical trials 2003;24(5):501-5.
2003: Gurm H S; Bhatt D L; Lincoff A M; Tcheng J E; Kereiakes D J; Kleiman N S; Jia G; Topol E J
Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.
Heart (British Cardiac Society) 2003;89(10):1200-4.
2003: Wong Cheuk-Kit; White Harvey D; Wilcox Robert G; Criger Douglas A; Califf Robert M; Topol Eric J; Ohman E Magnus
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.
Cardiac electrophysiology review 2003;7(3):201-7.
2003: Ross Mitchell J; Herrmann Howard C; Moliterno David J; Blankenship James C; Demopoulos Laura; DiBattiste Peter M; Ellis Stephen G; Ghazzal Ziyad; Martin Jack L; White Jennifer; Topol Eric J
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
Journal of the American College of Cardiology 2003;42(6):981-8.
2003: Kong David F; Hasselblad Vic; Harrington Robert A; White Harvey D; Tcheng James E; Kandzari David E; Topol Eric J; Califf Robert M
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.
The American journal of cardiology 2003;92(6):651-5.
2003: Yen Michael H; Bhatt Deepak L; Chew Derek P; Harrington Robert A; Newby L Kristin; Ardissino Diego; Van de Werf Frans; White Jennifer A; Moliterno David J; Topol Eric J
Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes.
The American journal of medicine 2003;115(4):318-21.
2003: Stenina Olga I; Desai Shailesh Y; Krukovets Irene; Kight Kelly; Janigro Damir; Topol Eric J; Plow Edward F
Thrombospondin-4 and its variants: expression and differential effects on endothelial cells.
Circulation 2003;108(12):1514-9.
2003: Chiu John H; Topol Eric J; Whitlow Patrick L; Hsu Amy P; Tuzcu E Murat; Franco Irving; Moliterno David J
Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization.
The American journal of cardiology 2003;92(5):582-3.
2003: Archacki Stephen R; Angheloiu George; Tian Xiao-Li; Tan Fen Lai; DiPaola Nick; Shen Gong-Qing; Moravec Christine; Ellis Stephen; Topol Eric J; Wang Qing
Identification of new genes differentially expressed in coronary artery disease by expression profiling.
Physiological genomics 2003;15(1):65-74.
2003: Ellis Keith; Tcheng James E; Sapp Shelly; Topol Eric J; Lincoff A Michael
Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials.
Journal of interventional cardiology 2003;16(4):299-305.
2003: Askari Arman T; Unzek Samuel; Popovic Zoran B; Goldman Corey K; Forudi Farhad; Kiedrowski Matthew; Rovner Aleksandr; Ellis Stephen G; Thomas James D; DiCorleto Paul E; Topol Eric J; Penn Marc S
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.
Lancet 2003;362(9385):697-703.
2003: Khot Umesh N; Khot Monica B; Bajzer Christopher T; Sapp Shelly K; Ohman E Magnus; Brener Sorin J; Ellis Stephen G; Lincoff A Michael; Topol Eric J
Prevalence of conventional risk factors in patients with coronary heart disease.
JAMA : the journal of the American Medical Association 2003;290(7):898-904.
2003: Saw Jacqueline; Steinhubl Steven R; Berger Peter B; Kereiakes Dean J; Serebruany Victor L; Brennan Danielle; Topol Eric J;
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Circulation 2003;108(8):921-4.
2003: L'Allier Philippe L; Aronow Herbert D; Cura Fernando A; Bhatt Deepak L; Albirini Abdulhay; Schneider Jakob P; Topol Eric J; Ellis Stephen G
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
The Canadian journal of cardiology 2003;19(9):1041-6.
2003: Tolleson Thaddeus R; Newby L Kristin; Harrington Robert A; Bhapkar Manjushri V; Verheugt Freek W A; Berger Peter B; Moliterno David J; White Harvey D; Ohman E Magnus; Van de Werf Frans; Topol Eric J; Califf Robert M;
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
The American journal of cardiology 2003;92(3):330-3.
2003: Shishehbor Mehdi H; Bhatt Deepak L; Topol Eric J
Using C-reactive protein to assess cardiovascular disease risk.
Cleveland Clinic journal of medicine 2003;70(7):634-40.
2003: Topol Eric J; Easton Donald; Harrington Robert A; Amarenco Pierre; Califf Robert M; Graffagnino Carmen; Davis Stephen; Diener Hans-Christophe; Ferguson James; Fitzgerald Desmond; Granett Jeffrey; Shuaib Ashfaq; Koudstaal Peter J; Theroux Pierre; Van de Werf Frans; Sigmon Kristina; Pieper Karen; Vallee Marc; Willerson James T;
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Circulation 2003;108(4):399-406.
2003: Bhatt Deepak L; Chew Derek P; Lincoff A Michael; Simoons Maarten L; Harrington Robert A; Ommen Steve R; Jia Gang; Topol Eric J;
Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes.
The American journal of cardiology 2003;92(2):136-40.
2003: Casserly Ivan P; Topol Eric J; Jia Gang; Lange Richard A; Hamm Christian; Meier Bernhard; DiBattiste Peter M; Lakkis Nasser; Chew Derek P; Stone Gregg W; Cohen David J; Moliterno David J
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
The American journal of cardiology 2003;92(2):125-9.
2003: James Stefan K; Lindahl Bertil; Siegbahn Agneta; Stridsberg Mats; Venge Per; Armstrong Paul; Barnathan Elliot S; Califf Robert; Topol Eric J; Simoons Maarten L; Wallentin Lars
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
Circulation 2003;108(3):275-81.
2003: Stenina Olga I; Krukovets Irene; Wang Kai; Zhou Zhongmin; Forudi Farhad; Penn Marc S; Topol Eric J; Plow Edward F
Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat.
Circulation 2003;107(25):3209-15.
2003: Vivekananthan Deepak P; Penn Marc S; Sapp Shelly K; Hsu Amy; Topol Eric J
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.
Lancet 2003;361(9374):2017-23.
2003: McCarthy J J; Lehner T; Reeves C; Moliterno D J; Newby L K; Rogers W J; Topol E J;
Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease.
Journal of medical genetics 2003;40(6):453-8.
2003: Yen Michael H; Topol Eric J
Atheromatous showers, periprocedural myocardial infarction, and fatality.
American heart journal 2003;145(6):933-5.
2003: Quinn Martin J; Byzova Tatiana V; Qin Jun; Topol Eric J; Plow Edward F
Integrin alphaIIbbeta3 and its antagonism.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(6):945-52.
2003: Mukherjee Debabrata; Topol Eric J
Pharmacogenomics in cardiovascular diseases.
Current problems in cardiology 2003;28(5):317-47.
2003: Lauer Michael S; Topol Eric J
Clinical trials--multiple treatments, multiple end points, and multiple lessons.
JAMA : the journal of the American Medical Association 2003;289(19):2575-7.
2003: Zhou Zhongmin; Wang Kai; Penn Marc S; Marso Steven P; Lauer Michael A; Forudi Farhad; Zhou Xiaorong; Qu Wu; Lu Yan; Stern David M; Schmidt Ann Marie; Lincoff A Michael; Topol Eric J
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury.
Circulation 2003;107(17):2238-43.
2003: Wang Kai; Kessler Paul D; Zhou Zhongmin; Penn Marc S; Forudi Farhad; Zhou Xiaorong; Tarakji Khaldoun; Kibbe Melina; Kovesdi Imre; Brough Douglas E; Topol Eric J; Lincoff A Michael
Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(5 Pt 1):597-603.
2003: Belch Jill J F; Topol Eric J; Agnelli Giancarlo; Bertrand Michel; Califf Robert M; Clement Denis L; Creager Mark A; Easton J Donald; Gavin James R; Greenland Philip; Hankey Graeme; Hanrath Peter; Hirsch Alan T; Meyer Jürgen; Smith Sidney C; Sullivan Frank; Weber Michael A;
Critical issues in peripheral arterial disease detection and management: a call to action.
Archives of internal medicine 2003;163(8):884-92.
2003: Chan Albert W; Bhatt Deepak L; Chew Derek P; Reginelli Joel; Schneider Jakob P; Topol Eric J; Ellis Stephen G
Relation of inflammation and benefit of statins after percutaneous coronary interventions.
Circulation 2003;107(13):1750-6.
2003: Brener Sorin J; Ellis Stephen G; Schneider Jakob; Apperson-Hansen Carolyn; Topol Eric J
Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry.
European heart journal 2003;24(7):630-8.
2003: Khadour Fadi H; Fu Yuling; Chang Wei-Ching; Ma Xin; Mark Dan; Granger Christopher B; Topol Eric J; Califf Robert M; Armstrong Paul W;
Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromes.
The Canadian journal of cardiology 2003;19(3):257-63.
2003: Al-Khatib Sana M; Stebbins Amanda L; Califf Robert M; Lee Kerry L; Granger Christopher B; White Harvey D; Armstrong Paul W; Topol Eric J; Ohman E Magnus;
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
American heart journal 2003;145(3):515-21.
2003: Topol Eric J; Kereiakes Dean J
Regionalization of care for acute ischemic heart disease: a call for specialized centers.
Circulation 2003;107(11):1463-6.
2003: Gum Patricia A; Kottke-Marchant Kandice; Welsh Patricia A; White Jennifer; Topol Eric J
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Journal of the American College of Cardiology 2003;41(6):961-5.
2003: James Stefan K; Armstrong Paul; Barnathan Elliott; Califf Robert; Lindahl Bertil; Siegbahn Agneta; Simoons Maarten L; Topol Eric J; Venge Per; Wallentin Lars;
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.
Journal of the American College of Cardiology 2003;41(6):916-24.
2003: You Sun-Ah; Archacki Stephen R; Angheloiu George; Moravec Christine S; Rao Shaoqi; Kinter Michael; Topol Eric J; Wang Qing
Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis.
Physiological genomics 2003;13(1):25-30.
2003: Cho Leslie; Chew Derek P; Moliterno David J; Roffi Marco; Ellis Stephen G; Franco Irving; Bajzer Christopher; Bhatt Deepak L; Dorosti Khosrow; Simpfendorder Conrad; Tuzcu Murat; Yadav Jay S; Brener Sorin; Raymond Russell; Whitlow Patrick; Topol Eric J; Lincoff A Michael
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
The American journal of cardiology 2003;91(6):742-3.
2003: Cho Leslie; Bhatt Deepak L; Brennan Danielle; Wilcox Robert G; Topol Eric J
Relation of insurance status to performance of coronary angiography in patients with unstable angina pectoris or acute myocardial infarction.
The American journal of cardiology 2003;91(6):721-3.
2003: Askari Arman T; Brennan Marie-Luise; Zhou Xiaorong; Drinko Jeanne; Morehead Annitta; Thomas James D; Topol Eric J; Hazen Stanley L; Penn Marc S
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.
The Journal of experimental medicine 2003;197(5):615-24.
2003: Cura Fernando A; Kapadia Samir R; L'Allier Philippe L; Ziada Khaled M; Mukherjee Debabrata; Wolski Katherine E; Yadav Jay S; Brener Sorin J; Whitlow Patrick L; Topol Eric J; Ellis Stephen G
Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival.
The American journal of cardiology 2003;91(5):587-90.
2003: Topol Eric J
Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding.
ACP journal club 2003;138(2):34.
2003: Casserly I P; Topol E J
The primacy of clinical effectiveness for cost effectiveness analysis.
Heart (British Cardiac Society) 2003;89(3):249-50.
2003: Topol Eric J
A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes.
Journal of the American College of Cardiology 2003;41(4 Suppl S):S123-9.
2003: Wang Kai; Zhou Xiaorong; Zhou Zhongmin; Tarakji Khaldoun; Carneiro Marcelo; Penn Marc S; Murray Daniel; Klein Allan; Humphries Robert G; Turner Jonathan; Thomas James D; Topol Eric J; Lincoff A Michael
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(2):357-62.
2003: Lincoff A Michael; Bittl John A; Harrington Robert A; Feit Frederick; Kleiman Neal S; Jackman J Daniel; Sarembock Ian J; Cohen David J; Spriggs Douglas; Ebrahimi Ramin; Keren Gadi; Carr Jeffrey; Cohen Eric A; Betriu Amadeo; Desmet Walter; Kereiakes Dean J; Rutsch Wolfgang; Wilcox Robert G; de Feyter Pim J; Vahanian Alec; Topol Eric J;
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
JAMA : the journal of the American Medical Association 2003;289(7):853-63.
2003: Cho Leslie; Bhatt Deepak L; Marso Steve P; Brennan Danielle; Holmes David R; Califf Robert M; Topol Eric J
An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial.
The American journal of medicine 2003;114(2):106-11.
2003: Kaul Padma; Newby L Kristin; Fu Yuling; Hasselblad Vic; Mahaffey Kenneth W; Christenson Robert H; Harrington Robert A; Ohman E Magnus; Topol Eric J; Califf Robert M; Van de Werf Frans; Armstrong Paul W;
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Journal of the American College of Cardiology 2003;41(3):371-80.
2003: Newby L K; Hasselblad V; Armstrong P W; Van de Werf F; Mark D B; White H D; Topol E J; Califf R M
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making.
European heart journal 2003;24(2):182-9.
2003: Newby L K; Bhapkar M V; White H D; Topol E J; Dougherty F C; Harrington R A; Smith M C; Asarch L F; Califf R M;
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes.
European heart journal 2003;24(2):172-81.
2003: Ottervanger J P; Armstrong P; Barnathan E S; Boersma E; Cooper J S; Ohman E M; James S; Topol E; Wallentin L; Simoons M L;
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Circulation 2003;107(3):437-42.
2003: Roffi Marco; Cattaneo Fabio; Topol Eric J
Thyrotoxicosis and the cardiovascular system: subtle but serious effects.
Cleveland Clinic journal of medicine 2003;70(1):57-63.
2003: Hasdai David; Topol Eric J; Kilaru Rakhi; Battler Alexander; Harrington Robert A; Vahanian Alec; Ohman E Magnus; Granger Christopher B; Van de Werf Frans; Simoons Maarten L; O'connor Christopher M; Holmes David R
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
American heart journal 2003;145(1):73-9.
2003: Bhatt Deepak L; Topol Eric J
Scientific and therapeutic advances in antiplatelet therapy.
Nature reviews. Drug discovery 2003;2(1):15-28.
2003: Guo Zheng; Li Xia; Rao Shaoqi; Moser Kathy L; Zhang Tianwen; Gong Binsheng; Shen Gongqing; Li Lin; Cannata Ruth; Zirzow Erich; Topol Eric J; Wang Qing
Multivariate sib-pair linkage analysis of longitudinal phenotypes by three step-wise analysis approaches.
BMC genetics 2003;4 Suppl 1():S68.
2003: Rao Shaoqi; Li Lin; Li Xia; Moser Kathy L; Guo Zheng; Shen Gongqing; Cannata Ruth; Zirzow Erich; Topol Eric J; Wang Qing
Genetic linkage analysis of longitudinal hypertension phenotypes using three summary measures.
BMC genetics 2003;4 Suppl 1():S24.
2003: Mukherjee Debabrata; Topol Eric J
Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors.
Arthritis research & therapy 2003;5(1):8-11.
2002: Mukherjee Debabrata; Mahaffey Kenneth W; Moliterno David J; Harrington Robert A; Yadav Jay S; Pieper Karen S; Gallup Dianne; Dyke Christopher; Roe Matthew T; Berdan Lisa; Lauer Michael S; Mänttäri Matti; White Harvey D; Califf Robert M; Topol Eric J
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
American heart journal 2002;144(6):995-1002.
2002: O'Shea J Conor; Wilcox Robert G; Skene Allan M; Stebbins Amanda L; Granger Christopher B; Armstrong Paul W; Bode Christoph; Ardissino Diego; Emanuelsson Hakan; Aylward Philip E; White Harvey D; Sadowski Zygmunt; Topol Eric J; Califf Robert M; Ohman E Magnus
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone.
The American journal of cardiology 2002;90(12):1374-7.
2002: Brener Sorin J; Lytle Bruce W; Schneider Jakob P; Ellis Stephen G; Topol Eric J
Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.
Journal of the American College of Cardiology 2002;40(11):1961-7.
2002: Roffi Marco; Mukherjee Debabrata; Chew Derek P; Bhatt Deepak L; Cho Leslie; Robbins Mark A; Ziada Khaled M; Brennan Danielle M; Ellis Stephen G; Topol Eric J
Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
Circulation 2002;106(24):3063-7.
2002: Mukherjee Debabrata; Nissen Steven E; Topol Eric J
Lack of cardioprotective effect of naproxen.
Archives of internal medicine 2002;162(22):2637; author reply 2638-9.
2002: Blankenship James C; Balog Craig; Sapp Shelly K; Califf Robert M; Lincoff A Michael; Tcheng James E; Topol Eric J
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2002;57(4):476-83.
2002: Mukherjee Debabrata; Gurm Hitinder; Tang W H Wilson; Roffi Marco; Wolski Kathy; Moliterno David J; Guetta Victor; Ardissinio Diego; Bode Christopher; Steg Gabriel; Lincoff A Michael; Topol Eric J
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
The American journal of cardiology 2002;90(11):1198-203.
2002: Steinhubl Steven R; Berger Peter B; Mann J Tift; Fry Edward T A; DeLago Augustin; Wilmer Charles; Topol Eric J;
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2002;288(19):2411-20.
2002: Topol Eric J
Economics and quality of care for patients with acute coronary syndromes: the impending crisis.
Clinical cardiology 2002;25(11 Suppl 1):I9-15.
2002: Lincoff A Michael; Califf Robert M; Van de Werf Frans; Willerson James T; White Harvey D; Armstrong Paul W; Guetta Victor; Gibler W Brian; Hochman Judith S; Bode Christoph; Vahanian Alec; Steg P Gabriel; Ardissino Diego; Savonitto Stefano; Bar Frits; Sadowski Zygmunt; Betriu Amadeo; Booth Joan E; Wolski Kathy; Waller Michael; Topol Eric J;
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
JAMA : the journal of the American Medical Association 2002;288(17):2130-5.
2002: Islam M Ashequl; Blankenship James C; Balog Craig; Iliadis Elias A; Lincoff A Michael; Tcheng James E; Califf Robert M; Topol Eric J;
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
The American journal of cardiology 2002;90(9):916-21.
2002: Lee Michael S; Wali Andreas U; Menon Venu; Berkowitz Scott D; Thompson Trevor D; Califf Robert M; Topol Eric J; Granger Christopher B; Hochman Judith S
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
Journal of thrombosis and thrombolysis 2002;14(2):91-101.
2002: Topol Eric J
Aspirin with bypass surgery--from taboo to new standard of care.
The New England journal of medicine 2002;347(17):1359-60.
2002: Bhatt Deepak L; Topol Eric J
The arterial inflammation hypothesis.
Archives of internal medicine 2002;162(19):2249-50; author reply 2250-1.
2002: Zhou Zhongmin; Penn Marc S; Forudi Farhad; Zhou Xiaorong; Tarakji Khaldoun; Topol Eric J; Lincoff A Michael; Wang Kai
Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(10):1598-603.
2002: Wong C-K; White H D; Wilcox R G; Criger D A; Califf R M; Topol E J; Ohman E M;
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
Heart (British Cardiac Society) 2002;88(4):357-62.
2002: Mukherjee Debabrata; Topol Eric J
The role of low-molecular-weight heparin in cardiovascular diseases.
Progress in cardiovascular diseases 2002;45(2):139-56.
2002: Mehta Rajendra H; Criger Douglas A; Granger Christopher B; Pieper Karen K; Califf Robert M; Topol Eric J; Bates Eric R
Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability.
Journal of the American College of Cardiology 2002;40(6):1034-40; discussion 1041-3.
2002: Agah Ramtin; Topol Eric J
Genetic testing for coronary heart disease: the approaching frontier.
Expert review of molecular diagnostics 2002;2(5):448-60.
2002: Kereiakes Dean J; Lincoff A Michael; Anderson Keaven M; Achenbach Robert; Patel Kamlesh; Barnathan Elliot; Califf Robert M; Topol Eric J;
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
The American journal of cardiology 2002;90(6):628-30.
2002: Bhatt Deepak L; Marso Steven P; Hirsch Alan T; Ringleb Peter A; Hacke Werner; Topol Eric J
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
The American journal of cardiology 2002;90(6):625-8.
2002: Ellis Stephen G; Chew Derek; Chan Albert; Whitlow Patrick L; Schneider Jakob P; Topol Eric J
Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy.
Circulation 2002;106(10):1205-10.
2002: Roffi M; Chew D P; Mukherjee D; Bhatt D L; White J A; Moliterno D J; Heeschen C; Hamm C W; Robbins M A; Kleiman N S; Théroux P; White H D; Topol E J
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
European heart journal 2002;23(18):1441-8.
2002: Newby L Kristin; Harrington Robert A; Bhapkar Manjushri V; Van de Werf Frans; Hochman Judith S; Granger Christopher B; Simes R John; Davis Catherine G; Topol Eric J; Califf Robert M; Moliterno David J;
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
Journal of thrombosis and thrombolysis 2002;14(1):33-42.
2002: Moliterno David J; Yakubov Steven J; DiBattiste Peter M; Herrmann Howard C; Stone Gregg W; Macaya Carlos; Neumann Franz-Josef; Ardissino Diego; Bassand Jean-Pierre; Borzi Lynn; Yeung Alan C; Harris Katherine A; Demopoulos Laura A; Topol Eric J;
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Lancet 2002;360(9330):355-60.
2002: Chan Albert W; Quinn Martin J; Bhatt Deepak L; Chew Derek P; Moliterno David J; Topol Eric J; Ellis Stephen G
Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention.
Journal of the American College of Cardiology 2002;40(4):669-75.
2002: Kottke-Marchant K; Bahit M C; Granger C B; Zoldhelyi P; Ardissino D; Brooks L; Griffin J H; Potthoff R F; Van de Werf F; Califf R M; Topol E J
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
European heart journal 2002;23(15):1202-12.
2002: Wang Kai; Zhou Xiaorong; Zhou Zhongmin; Tarakji Khaldoun; Qin Jian Xin; Sitges Marta; Shiota Takahiro; Forudi Farhad; Schaub Robert G; Kumar Anjali; Penn Marc S; Topol Eric J; Lincoff A Michael
Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion.
Thrombosis and haemostasis 2002;88(1):149-54.
2002: Penn Marc S; Francis Gary S; Ellis Stephen G; Young James B; McCarthy Patrick M; Topol Eric J
Autologous cell transplantation for the treatment of damaged myocardium.
Progress in cardiovascular diseases 2002;45(1):21-32.
2002: Quinn Martin J; Plow Edward F; Topol Eric J
Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?
Circulation 2002;106(3):379-85.
2002: Al-Khatib Sana M; Granger Christopher B; Huang Yao; Lee Kerry L; Califf Robert M; Simoons Maarten L; Armstrong Paul W; Van de Werf Frans; White Harvey D; Simes R John; Moliterno David J; Topol Eric J; Harrington Robert A
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
Circulation 2002;106(3):309-12.
2002: Topol Eric J; Lincoff A Michael; Kereiakes Dean J; Kleiman Neal S; Cohen Eric A; Ferguson James J; Tcheng James E; Sapp Shelly; Califf Robert M
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
The American journal of medicine 2002;113(1):1-6.
2002: Anderson R David; White Harvey D; Ohman E Magnus; Wagner Galen S; Krucoff Mitchell W; Armstrong Paul W; Weaver W Douglas; Gibler W Brian; Stebbins Amanda L; Califf Robert M; Topol Eric J
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.
American heart journal 2002;144(1):81-8.
2002: Bhatt Deepak L; Topol Eric J
Need to test the arterial inflammation hypothesis.
Circulation 2002;106(1):136-40.
2002: Gurm Hitinder S; Brennan Danielle M; Booth Joan; Tcheng James E; Lincoff A Michael; Topol Eric J
Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox).
The American journal of cardiology 2002;90(1):42-5.
2002: Aviles Ronnier J; Askari Arman T; Lindahl Bertil; Wallentin Lars; Jia Gang; Ohman E Magnus; Mahaffey Kenneth W; Newby L Kristin; Califf Robert M; Simoons Maarten L; Topol Eric J; Berger Peter; Lauer Michael S
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
The New England journal of medicine 2002;346(26):2047-52.
2002: Ronner Eelko; Boersma Eric; Laarman Gert-Jan; Somsen G Aernout; Harrington Robert A; Deckers Jaap W; Topol Eric J; Califf Robert M; Simoons Maarten L
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Journal of the American College of Cardiology 2002;39(12):1924-9.
2002: Jeremias Allen; Albirini Abdulhay; Ziada Khaled M; Chew Derek P; Brener Sorin J; Topol Eric J; Ellis Stephen G
Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction.
American heart journal 2002;143(6):1040-5.
2002: Tamberella Michael R; Bhatt Deepak L; Chew Derek P; Kereiakes Dean J; Topol Eric J; Steinhubl Steven R;
Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study).
The American journal of cardiology 2002;89(12):1429-31.
2002: Roffi Marco; Moliterno David J; Meier Bernhard; Powers Eric R; Grines Cindy L; DiBattiste Peter M; Herrmann Howard C; Bertrand Michel; Harris Katherine E; Demopoulos Laura A; Topol Eric J;
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Circulation 2002;105(23):2730-6.
2002: Brener S J; Ellis S G; Schneider J; Topol E J
Frequency and long-term impact of myonecrosis after coronary stenting.
European heart journal 2002;23(11):869-76.
2002: Moliterno D J; Topol E J
The TARGET trial: hit or miss?
European heart journal 2002;23(11):835-7.
2002: Cantor Warren J; Newby L Kristin; Christenson Robert H; Tuttle Robert H; Hasselblad Vic; Armstrong Paul W; Moliterno David J; Califf Robert M; Topol Eric J; Ohman E Magnus;
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
Journal of the American College of Cardiology 2002;39(11):1738-44.
2002: Mukherjee Debabrata; Topol Eric J
Pharmacogenomics in cardiovascular diseases.
Progress in cardiovascular diseases 2002;44(6):479-98.
2002: Lincoff A Michael; Kleiman Neal S; Kottke-Marchant Kandace; Maierson Elizabeth S; Maresh Kelly; Wolski Katherine E; Topol Eric J
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
American heart journal 2002;143(5):847-53.
2002: Stone Gregg W; Moliterno David J; Bertrand Michel; Neumann Franz-Josef; Herrmann Howard C; Powers Eric R; Grines Cindy L; Moses Jeffrey W; Cohen David J; Cohen Eric A; Cohen Marc; Wolski Kathy; DiBattiste Peter M; Topol Eric J
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Circulation 2002;105(20):2347-54.
2002: Jeremias Allen; Bhatt Deepak L; Chew Derek P; Ziada Khaled M; Albirini Abdulhay; Brener Sorin J; Lincoff A Michael; Topol Eric J; Ellis Stephen G
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
The American journal of cardiology 2002;89(10):1209-11.
2002: Yoon Jung Han; Wu Chiung Jen; Homme James; Tuch Ronald J; Wolff Rodney G; Topol Eric J; Lincoff A Michael
Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model.
Yonsei medical journal 2002;43(2):242-51.
2002: Ellis Stephen G; Lincoff A Michael; Whitlow Patrick L; Raymond Russell E; Franco Irving; Schneider Jakob P; Topol Eric J
Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting.
The American journal of cardiology 2002;89(8):937-40.
2002: Lauer Michael A; Karweit Jennifer A; Cascade Elisa F; Lin Nancy D; Topol Eric J
Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997.
The American journal of cardiology 2002;89(8):924-9.
2002: Mazur Wojciech; Kaluza Grzegorz L; Sapp Shelly; Balog Craig; Topol Eric J; Mark Daniel B; Ellis Stephen G; Kereiakes Dean J; Lincoff A Michael; Kleiman Neal S
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.
American heart journal 2002;143(4):594-601.
2002: Estess J M; Topol E J
Fibrinolytic treatment for elderly patients with acute myocardial infarction.
Heart (British Cardiac Society) 2002;87(4):308-11.
2002: Casserly I P; Topol E J
Glycoprotein IIb/IIIa antagonists--from bench to practice.
Cellular and molecular life sciences : CMLS 2002;59(3):478-500.
2002: Ellis Stephen G; Schneider Jakob P; Topol Eric J
Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated.
The American journal of cardiology 2002;89(6):751-3.
2002: Zhou Zhongmin; Lauer Michael A; Wang Kai; Forudi Farhad; Zhou Xiaorong; Song Xiao yu; Solowski Nancy; Kapadia Samir R; Nakada Marian T; Topol Eric J; Lincoff A Michael
Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model.
Atherosclerosis 2002;161(1):153-9.
2002: Chan Albert W; Bhatt Deepak L; Chew Derek P; Quinn Martin J; Moliterno David J; Topol Eric J; Ellis Stephen G
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention.
Circulation 2002;105(6):691-6.
2002: Mahaffey Kenneth W; Roe Matthew T; Dyke Christopher K; Newby L Kristin; Kleiman Neal S; Connolly Patty; Berdan Lisa G; Sparapani Rodney; Lee Kerry L; Armstrong Paul W; Topol Eric J; Califf Robert M; Harrington Robert A
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
American heart journal 2002;143(2):242-8.
2002: Gibler W Brian; Topol Eric J; Holroyd Brian; Armstrong Paul W
Cardiology and emergency medicine: united we stand, divided we fall.
Annals of emergency medicine 2002;39(2):164-7.
2002: Gibler W Brian; Armstrong Paul W; Ohman E Magnus; Weaver W Douglas; Stebbins Amanda L; Gore Joel M; Newby L Kristin; Califf Robert M; Topol Eric J;
Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience.
Annals of emergency medicine 2002;39(2):123-30.
2002: Brener Sorin J; Zeymer Uwe; Adgey A A Jennifer; Vrobel Thomas R; Ellis Stephen G; Neuhaus Karl Ludwig; Juran Nadine; Ivanc Thomas B; Ohman E Magnus; Strony John; Kitt Michael; Topol Eric J
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
Journal of the American College of Cardiology 2002;39(3):377-86.
2002: Brener S J; Topol E J
Epicardial versus microcirculatory dissociation.
European heart journal 2002;23(4):274-6.
2002: Ronner E; Boersma E; Akkerhuis K M; Harrington R A; Lincoff A M; Deckers J W; Karsch K; Kleiman N S; Vahanian A; Topol E J; Califf R M; Simoons M L
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
European heart journal 2002;23(3):239-46.
2002: Boersma Eric; Harrington Robert A; Moliterno David J; White Harvey; Théroux Pierre; Van de Werf Frans; de Torbal Anneke; Armstrong Paul W; Wallentin Lars C; Wilcox Robert G; Simes John; Califf Robert M; Topol Eric J; Simoons Maarten L
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Lancet 2002;359(9302):189-98.
2002: Labinaz Marino; Kilaru Rakhi; Pieper Karen; Marso Steven P; Kitt Michael M; Simoons Maarten L; Califf Robert M; Topol Eric J; Armstrong Paul W; Harrington Robert A
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Circulation 2002;105(3):322-7.
2002: Chan Albert W; Chew Derek P; Bhatt Deepak L; Moliterno David J; Topol Eric J; Ellis Stephen G
Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.
The American journal of cardiology 2002;89(2):132-6.
2002: Savonitto Stefano; Granger Christopher B; Ardissino Diego; Gardner Laura; Cavallini Claudio; Galvani Marcello; Ottani Filippo; White Harvey D; Armstrong Paul W; Ohman E Magnus; Pieper Karen S; Califf Robert M; Topol Eric J;
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.
Journal of the American College of Cardiology 2002;39(1):22-9.
2002: Bhatt Deepak L; Bertrand Michel E; Berger Peter B; L'Allier Philippe L; Moussa Issam; Moses Jeffrey W; Dangas George; Taniuchi Megumi; Lasala John M; Holmes David R; Ellis Stephen G; Topol Eric J
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
Journal of the American College of Cardiology 2002;39(1):9-14.
2002: Breeman Arno; Mercado Nestor; Lenzen Mattie; van den Brand Marcel M J; Harrington Robert A; Califf Robert M; Topol Eric J; Simoons Maarten L; Boersma Eric;
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Cardiology 2002;98(4):195-201.
2002: Dauterman Kent; Topol Eric
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
Annals of medicine 2002;34(7-8):514-22.
2002: Robbins Mark; Topol Eric J
Inflammation in acute coronary syndromes.
Cleveland Clinic journal of medicine 2002;69 Suppl 2():SII130-42.
2001: Roe M T; Granger C B; Puma J A; Hellkamp A S; Hochman J S; Ohman E M; White H D; Van de Werf F; Armstrong P W; Ellis S G; Califf R M; Topol E J
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention.
The American journal of cardiology 2001;88(12):1403-6, A6.
2001: Lauer M A; Houghtaling P L; Peterson J G; Granger C B; Bhatt D L; Sapp S K; Simoons M L; Harrington R A; Topol E J; Lincoff A M;
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Circulation 2001;104(23):2772-7.
2001: Roffi M; Chew D P; Mukherjee D; Bhatt D L; White J A; Heeschen C; Hamm C W; Moliterno D J; Califf R M; White H D; Kleiman N S; Théroux P; Topol E J
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
Circulation 2001;104(23):2767-71.
2001: Bhatt D L; Kapadia S R; Bajzer C T; Chew D P; Ziada K M; Mukherjee D; Roffi M; Topol E J; Yadav J S
Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting.
The Journal of invasive cardiology 2001;13(12):767-71.
2001: Bittl J A; Chaitman B R; Feit F; Kimball W; Topol E J
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
American heart journal 2001;142(6):952-9.
2001: Chew D P; Roffi M; Topol E J
Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.
Progress in cardiovascular diseases 2001;44(3):195-206.
2001: Ellis S G; Brener S J; Lincoff A M; Moliterno D J; Whitlow P L; Schneider J P; Topol E J
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise.
Circulation 2001;104(22):2685-8.
2001: Topol E J; McCarthy J; Gabriel S; Moliterno D J; Rogers W J; Newby L K; Freedman M; Metivier J; Cannata R; O'Donnell C J; Kottke-Marchant K; Murugesan G; Plow E F; Stenina O; Daley G Q
Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction.
Circulation 2001;104(22):2641-4.
2001: Quinn M J; Topol E J
Common variations in platelet glycoproteins: pharmacogenomic implications.
Pharmacogenomics 2001;2(4):341-52.
2001: Mukherjee D; Nissen S E; Topol E J
Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution.
Cleveland Clinic journal of medicine 2001;68(11):963-4.
2001: Zhang R; Brennan M L; Fu X; Aviles R J; Pearce G L; Penn M S; Topol E J; Sprecher D L; Hazen S L
Association between myeloperoxidase levels and risk of coronary artery disease.
JAMA : the journal of the American Medical Association 2001;286(17):2136-42.
2001: Chew D P; Bhatt D L; Robbins M A; Mukherjee D; Roffi M; Schneider J P; Topol E J; Ellis S G
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.
The American journal of cardiology 2001;88(6):672-4.
2001: Hudson M P; Granger C B; Topol E J; Pieper K S; Armstrong P W; Barbash G I; Guerci A D; Vahanian A; Califf R M; Ohman E M
Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
Circulation 2001;104(11):1229-35.
2001: Chew D P; Bhatt D L; Robbins M A; Penn M S; Schneider J P; Lauer M S; Topol E J; Ellis S G
Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention.
Circulation 2001;104(9):992-7.
2001: Mukherjee D; Nissen S E; Topol E J
Risk of cardiovascular events associated with selective COX-2 inhibitors.
JAMA : the journal of the American Medical Association 2001;286(8):954-9.
2001: Park S H; Marso S P; Zhou Z; Foroudi F; Topol E J; Lincoff A M
Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus.
Circulation 2001;104(7):815-9.
2001: Wang K; Zhou Z; Zhou X; Tarakji K; Topol E J; Lincoff A M
Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model.
Journal of the American College of Cardiology 2001;38(2):577-82.
2001: Topol E
Recent advances in anticoagulant therapy for acute coronary syndromes.
American heart journal 2001;142(2 Suppl):S22-9.
2001: Gum P A; Kottke-Marchant K; Poggio E D; Gurm H; Welsh P A; Brooks L; Sapp S K; Topol E J
Profile and prevalence of aspirin resistance in patients with cardiovascular disease.
The American journal of cardiology 2001;88(3):230-5.
2001: Kaul P; Fu Y; Chang W C; Harrington R A; Wagner G S; Goodman S G; Granger C B; Moliterno D J; Van de Werf F; Califf R M; Topol E J; Armstrong P W;
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.
Journal of the American College of Cardiology 2001;38(1):64-71.
2001: Cura F A; L'Allier P L; Kapadia S R; Houghtaling P L; Dipaola L M; Ellis S G; Topol E J; Brener S J;
Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction.
The American journal of cardiology 2001;88(2):124-8.
2001: Lincoff A M; Kereiakes D J; Mascelli M A; Deckelbaum L I; Barnathan E S; Patel K K; Frederick B; Nakada M T; Topol E J
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
Circulation 2001;104(2):163-7.
2001: Penn M S; Topol E J
Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling.
Circulation research 2001;89(1):1-2.
2001: Akkerhuis K M; Deckers J W; Lincoff A M; Tcheng J E; Boersma E; Anderson K; Balog C; Califf R M; Topol E J; Simoons M L
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
JAMA : the journal of the American Medical Association 2001;286(1):78-82.
2001: Lundergan C F; Ross A M; McCarthy W F; Reiner J S; Boyle D; Fink C; Califf R M; Topol E J; Simoons M L; Van Den Brand M; Van de Werf F; Coyne K S;
Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience.
American heart journal 2001;142(1):43-50.
2001: Al-Khatib S M; Pieper K S; Lee K L; Mahaffey K W; Hochman J S; Pepine C J; Kopecky S L; Akkerhuis M; Stepinska J; Simoons M L; Topol E J; Califf R M; Harrington R A
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.
The American journal of cardiology 2001;88(1):A7, 76-9.
2001: Topol E J;
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Lancet 2001;357(9272):1905-14.
2001: Anderson K M; Califf R M; Stone G W; Neumann F J; Montalescot G; Miller D P; Ferguson J J; Willerson J T; Weisman H F; Topol E J
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.
Journal of the American College of Cardiology 2001;37(8):2059-65.
2001: Topol E J; Moliterno D J; Herrmann H C; Powers E R; Grines C L; Cohen D J; Cohen E A; Bertrand M; Neumann F J; Stone G W; DiBattiste P M; Demopoulos L;
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
The New England journal of medicine 2001;344(25):1888-94.
2001: Newby L K; Ohman E M; Christenson R H; Moliterno D J; Harrington R A; White H D; Armstrong P W; Van De Werf F; Pfisterer M; Hasselblad V; Califf R M; Topol E J
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
Circulation 2001;103(24):2891-6.
2001: Patel V B; Robbins M A; Topol E J
C-reactive protein: a 'golden marker' for inflammation and coronary artery disease.
Cleveland Clinic journal of medicine 2001;68(6):521-524, 527-34.
2001: Topol E J
Introduction.
The Journal of invasive cardiology 2001;13 Suppl A():2A.
2001: Aronow H D; Topol E J; Roe M T; Houghtaling P L; Wolski K E; Lincoff A M; Harrington R A; Califf R M; Ohman E M; Kleiman N S; Keltai M; Wilcox R G; Vahanian A; Armstrong P W; Lauer M S
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
Lancet 2001;357(9262):1063-8.
2001: Jeremias A; Casserly I; Estess J M; Smedira N G; Topol E J
Acute myocardial infarction after aortic valve endocarditis.
The American journal of medicine 2001;110(5):417-8.
2001: Cho L; Bhatt D L; Wolski K; Lincoff M; Topol E J; Moliterno D J
Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
American heart journal 2001;141(4):599-602.
2001: Pilote L; Miller D P; Califf R M; Topol E J;
Recurrent ischemia after thrombolysis for acute myocardial infarction.
American heart journal 2001;141(4):559-65.
2001: Topol E J
Conflict-of-interest policies.
The New England journal of medicine 2001;344(13):1017; author reply 1018.
2001: Bahit M C; Topol E J; Califf R M; Armstrong P W; Criger D A; Hasselblad V; Betriu A; Hirsh J; Ardissino D; Granger C B
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes.
Journal of the American College of Cardiology 2001;37(4):1001-7.
2001: Steinhubl S R; Ellis S G; Wolski K; Lincoff A M; Topol E J
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.
Circulation 2001;103(10):1403-9.
2001: Labinaz M; Sketch M H; Ellis S G; Abramowitz B M; Stebbins A L; Pieper K S; Holmes D R; Califf R M; Topol E J
Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy.
American heart journal 2001;141(3):469-77.
2001: Cohen M G; Pacchiana C M; Corbalán R; Perez J E; Ponte C I; Oropeza E S; Diaz R; Paolasso E; Izasa D; Rodas M A; Urrutia C E; Harrington R A; Topol E J; Califf R M
Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial.
American heart journal 2001;141(3):391-401.
2001: Peterson J G; Topol E J; Roe M T; Sapp S K; Lincoff A M; Deckers J W; Blackstone E H; Harrington R A; Califf R M; Lauer M S
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
The American journal of cardiology 2001;87(5):532-6.
2001: Greenbaum A B; Harrington R A; Hudson M P; MacAulay C M; Wilcox R G; Simoons M L; Berdan L G; Guerci A; Cokkinos D V; Kitt M M; Lincoff A M; Topol E J; Califf R M; Ohman E M
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
Journal of the American College of Cardiology 2001;37(2):492-8.
2001: Chew D P; Bhatt D L; Lincoff A M; Moliterno D J; Brener S J; Wolski K E; Topol E J
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Circulation 2001;103(7):961-6.
2001: Barbash G I; Birnbaum Y; Bogaerts K; Hudson M; Lesaffre E; Fu Y; Goodman S; Houbracken K; Munsters K; Granger C B; Pieper K; Califf R M; Topol E J; Van De Werf F
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
Circulation 2001;103(7):954-60.
2001: Chew D P; Bhatt D L; Sapp S; Topol E J
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Circulation 2001;103(2):201-6.
2001: Bhatt D L; Chew D P; Hirsch A T; Ringleb P A; Hacke W; Topol E J
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
Circulation 2001;103(3):363-8.
2001: Chew D P; Bhatt D L; Topol E J
Oral glycoprotein IIb/IIIa inhibitors: why don't they work?
American journal of cardiovascular drugs : drugs, devices, and other interventions 2001;1(6):421-8.
2000: Topol E J
The role of bivalirudin in percutaneous coronary intervention.
The Journal of invasive cardiology 2000;12 Suppl F():1F.
2000: Marso S P; Bhatt D L; Roe M T; Houghtaling P L; Labinaz M; Kleiman N S; Dyke C; Simmoons M L; Califf R M; Harrington R A; Topol E J
Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators.
Circulation 2000;102(24):2952-8.
2000: Lincoff A M; Mark D B; Tcheng J E; Califf R M; Bala M V; Anderson K M; Davidson-Ray L; Knight J D; Cabot C F; Topol E J
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Circulation 2000;102(24):2923-9.
2000: Yamada D M; Topol E J
Importance of microembolization and inflammation in atherosclerotic heart disease.
American heart journal 2000;140(6 Suppl):S90-102.
2000: Wong C K; White H D; Wilcox R G; Criger D A; Califf R M; Topol E J; Ohman E M
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience.
American heart journal 2000;140(6):878-85.
2000: Menon V; Hochman J S; Stebbins A; Pfisterer M; Col J; Anderson R D; Hasdai D; Holmes D R; Bates E R; Topol E J; Califf R M; Ohman E M
Lack of progress in cardiogenic shock: lessons from the GUSTO trials.
European heart journal 2000;21(23):1928-36.
2000: Topol E J
The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.
Clinical cardiology 2000;23 Suppl 6():VI-23-8.
2000: Herrmann H C; Moliterno D J; Ohman E M; Stebbins A L; Bode C; Betriu A; Forycki F; Miklin J S; Bachinsky W B; Lincoff A M; Califf R M; Topol E J
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
Journal of the American College of Cardiology 2000;36(5):1489-96.
2000: Mukherjee D; Reginelli J P; Moliterno D J; Yadav J S; Schneider J P; Raymond R; Whitlow P L; Franco I; Topol E J; Ellis S G
Unexpected mortality reduction with abciximab for in-stent restenosis.
The Journal of invasive cardiology 2000;12(11):540-4.
2000: Moliterno D J; Topol E J
A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
American heart journal 2000;140(5):722-6.
2000: McGuire D K; Emanuelsson H; Granger C B; Magnus Ohman E; Moliterno D J; White H D; Ardissino D; Box J W; Califf R M; Topol E J
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators.
European heart journal 2000;21(21):1750-8.
2000: Chang W C; Fu Y; Ohman E M; Gupta M; Morris A; Roth S N; Granger C B; Califf R M; Topol E J; Mark D B; Armstrong P W
Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators.
The Canadian journal of cardiology 2000;16(10):1231-9.
2000: Topol E J; Ohman E M; Armstrong P W; Wilcox R; Skene A M; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White H D; Hochman J S; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno D J; Califf R M
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
Circulation 2000;102(15):1761-5.
2000: Peterson J G; Topol E J; Sapp S K; Young J B; Lincoff A M; Lauer M S
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
The American journal of medicine 2000;109(5):371-7.
2000: Cura F A; Kapadia S R; L'Allier P L; Schneider J P; Kreindel M S; Silver M J; Yadav J S; Simpfendorfer C C; Raymond R R; Tuzcu E M; Franco I; Whitlow P L; Topol E J; Ellis S G
Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade.
The American journal of cardiology 2000;86(7):780-2, A9.
2000: Cho L; Marso S P; Bhatt D L; Topol E J
Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
Journal of women's health & gender-based medicine 2000;9(7):741-6.
2000: Bhatt D L; Topol E J
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
JAMA : the journal of the American Medical Association 2000;284(12):1549-58.
2000: Fu Y; Chang W C; Mark D; Califf R M; Mackenzie B; Granger C B; Topol E J; Hlatky M; Armstrong P W
Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators.
Circulation 2000;102(12):1375-81.
2000: Hasdai D; Harrington R A; Hochman J S; Califf R M; Battler A; Box J W; Simoons M L; Deckers J; Topol E J; Holmes D R
Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation.
Journal of the American College of Cardiology 2000;36(3):685-92.
2000: Roe M T; Harrington R A; Prosper D M; Pieper K S; Bhatt D L; Lincoff A M; Simoons M L; Akkerhuis M; Ohman E M; Kitt M M; Vahanian A; Ruzyllo W; Karsch K; Califf R M; Topol E J
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
Circulation 2000;102(10):1101-6.
2000: Lincoff A M; Harrington R A; Califf R M; Hochman J S; Guerci A D; Ohman E M; Pepine C J; Kopecky S L; Kleiman N S; Pacchiana C M; Berdan L G; Kitt M M; Simoons M L; Topol E J
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Circulation 2000;102(10):1093-100.
2000: Sgarbossa E B; Meyer P M; Pinski S L; Pavlovic-Surjancev B; Barbagelata A; Goodman S G; Lum A S; Underwood D A; Gates K B; Califf R M; Topol E J; Wagner G S
Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate.
American heart journal 2000;140(3):385-94.
2000: Hasdai D; Topol E J; Califf R M; Berger P B; Holmes D R
Cardiogenic shock complicating acute coronary syndromes.
Lancet 2000;356(9231):749-56.
2000: Reginelli J P; Topol E J
Glycoprotein IIb/IIIa inhibitors: current indications and future prospects.
The American journal of medicine 2000;109(3):252-4.
2000: Lincoff A M; LeNarz L A; Despotis G J; Smith P K; Booth J E; Raymond R E; Sapp S K; Cabot C F; Tcheng J E; Califf R M; Effron M B; Topol E J
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
The Annals of thoracic surgery 2000;70(2):516-26.
2000: Harrington R A; Armstrong P W; Graffagnino C; Van De Werf F; Kereiakes D J; Sigmon K N; Card T; Joseph D M; Samuels R; Granett J; Chan R; Califf R M; Topol E J
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
Circulation 2000;102(7):728-35.
2000: Cho L; Topol E J; Balog C; Foody J M; Booth J E; Cabot C; Kleiman N S; Tcheng J E; Califf R; Lincoff A M
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Journal of the American College of Cardiology 2000;36(2):381-6.
2000: Brener S J; Topol E J
Troponin, embolization and restoration of microvascular integrity.
European heart journal 2000;21(14):1117-9.
2000: Sane D C; Damaraju L V; Topol E J; Cabot C F; Mascelli M A; Harrington R A; Simoons M L; Califf R M
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
Journal of the American College of Cardiology 2000;36(1):75-83.
2000: Cura F A; Bhatt D L; Lincoff A M; Kapadia S R; L'Allier P L; Ziada K M; Wolski K E; Moliterno D J; Brener S J; Ellis S G; Topol E J
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
Circulation 2000;102(1):28-34.
2000: Kereiakes D J; Berkowitz S D; Lincoff A M; Tcheng J E; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf R M; Topol E J
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
American heart journal 2000;140(1):74-80.
2000: Bhatt D L; Hirsch A T; Ringleb P A; Hacke W; Topol E J
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
American heart journal 2000;140(1):67-73.
2000: Brieger D B; Mak K H; Miller D P; Califf R M; Topol E J
Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators.
American heart journal 2000;140(1):29-33.
2000: Boersma E; Pieper K S; Steyerberg E W; Wilcox R G; Chang W C; Lee K L; Akkerhuis K M; Harrington R A; Deckers J W; Armstrong P W; Lincoff A M; Califf R M; Topol E J; Simoons M L
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Circulation 2000;101(22):2557-67.
2000: Marso S P; Ellis S G; Gurm H S; Lytle B W; Topol E J
Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting.
American heart journal 2000;139(6):939-44.
2000: Topol E J; Easton J D; Amarenco P; Califf R; Harrington R; Graffagnino C; Davis S; Diener H C; Ferguson J; Fitzgerald D; Shuaib A; Koudstaal P J; Theroux P; Van de Werf F; Willerson J T; Chan R; Samuels R; Ilson B; Granett J
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
American heart journal 2000;139(6):927-33.
2000: Lincoff A M; Topol E J
Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
European heart journal 2000;21(11):863-7.
2000: Califf R M; Pieper K S; Lee K L; Van De Werf F; Simes R J; Armstrong P W; Topol E J
Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.
Circulation 2000;101(19):2231-8.
2000: Hasdai D; Granger C B; Srivatsa S S; Criger D A; Ellis S G; Califf R M; Topol E J; Holmes D R
Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes.
Journal of the American College of Cardiology 2000;35(6):1502-12.
2000: Hasdai D; Holmes D R; Criger D A; Topol E J; Califf R M; Harrington R A
Age and outcome after acute coronary syndromes without persistent ST-segment elevation.
American heart journal 2000;139(5):858-66.
2000: Bhatt D L; Lincoff A M; Califf R M; Simoons M L; Tcheng J E; Brener S J; Wolski K E; Topol E J
The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
The American journal of cardiology 2000;85(9):1060-4.
2000: Lincoff A M; Califf R M; Topol E J
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Journal of the American College of Cardiology 2000;35(5):1103-15.
2000: Batchelor W B; Granger C B; Kleiman N S; Phillips H R; Ellis S G; Betriu A; Criger D A; Stebbins A L; Topol E J; Califf R M;
A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes.
The American journal of cardiology 2000;85(6):692-7.
2000: Christenson R H; Vollmer R T; Ohman E M; Peck S; Thompson T D; Duh S H; Ellis S G; Newby L K; Topol E J; Califf R M
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group.
The American journal of cardiology 2000;85(5):543-7.
2000: Bhatt D L; Marso S P; Lincoff A M; Wolski K E; Ellis S G; Topol E J
Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
Journal of the American College of Cardiology 2000;35(4):922-8.
2000: Topol E J
Inflammation and embolization in ischemic heart disease.
The Journal of invasive cardiology 2000;12 Suppl B():2B-7B.
2000: Newby L K; Eisenstein E L; Califf R M; Thompson T D; Nelson C L; Peterson E D; Armstrong P W; Van de Werf F; White H D; Topol E J; Mark D B
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
The New England journal of medicine 2000;342(11):749-55.
2000: Bruce C J; Kuntz R E; Popma J J; Pieper K S; Topol E J; Holmes D R
Application of a continuous regression model of restenosis to saphenous vein grafts after successful percutaneous transluminal coronary angioplasty or directional coronary atherectomy.
Journal of the American College of Cardiology 2000;35(3):619-23.
2000: Mak K H; Topol E J
Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus.
Journal of the American College of Cardiology 2000;35(3):563-8.
2000: Gebel J M; Brott T G; Sila C A; Tomsick T A; Jauch E; Salisbury S; Khoury J; Miller R; Pancioli A; Duldner J E; Topol E J; Broderick J P
Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage.
Stroke; a journal of cerebral circulation 2000;31(3):596-600.
2000: Brener S J; Ellis S G; Sapp S K; Betriu A; Granger C B; Burchenal J E; Moliterno D J; Califf R M; Topol E J
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials.
American heart journal 2000;139(3):476-81.
2000: Hasdai D; Holmes D R; Criger D A; Topol E J; Califf R M; Wilcox R G; Paolasso E; Simoons M; Deckers J; Harrington R A
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
American heart journal 2000;139(3):454-60.
2000: Akkerhuis K M; Deckers J W; Boersma E; Harrington R A; Stepinska J; Mahaffey K W; Wilcox R G; Lincoff A M; Keltai M; Topol E J; Califf R M; Simoons M L
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
European heart journal 2000;21(5):371-81.
2000: Bhatt D L; Topol E J
Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution.
The American journal of medicine 2000;108(2):176-7.
2000: Thel M C; Califf R M; Tardiff B E; Gardner L H; Sigmon K N; Lincoff A M; Topol E J; Kitt M M; Blankenship J C; Tcheng J E
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
The American journal of cardiology 2000;85(4):427-34.
2000: Kleiman N S; Lincoff A M; Flaker G C; Pieper K S; Wilcox R G; Berdan L G; Lorenz T J; Cokkinos D V; Simoons M L; Boersma E; Topol E J; Califf R M; Harrington R A
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
Circulation 2000;101(7):751-7.
2000: Topol E J; Yadav J S
Recognition of the importance of embolization in atherosclerotic vascular disease.
Circulation 2000;101(5):570-80.
2000: Mark D B; Harrington R A; Lincoff A M; Califf R M; Nelson C L; Tsiatis A A; Buell H; Mahaffey K W; Davidson-Ray L; Topol E J
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
Circulation 2000;101(4):366-71.
2000: Braunwald E; Califf R M; Cannon C P; Fox K A; Fuster V; Gibler W B; Harrington R A; King S B; Kleiman N S; Theroux P; Topol E J; Van de Werf F; White H D; Willerson J T
Redefining medical treatment in the management of unstable angina.
The American journal of medicine 2000;108(1):41-53.
2000: Bhatt D L; Topol E J
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
The Medical clinics of North America 2000;84(1):163-79, ix.
2000: Alexander J H; Sparapani R A; Mahaffey K W; Deckers J W; Newby L K; Ohman E M; Corbalán R; Chierchia S L; Boland J B; Simoons M L; Califf R M; Topol E J; Harrington R A
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
JAMA : the journal of the American Medical Association 2000;283(3):347-53.
2000: Hasdai D; Califf R M; Thompson T D; Hochman J S; Ohman E M; Pfisterer M; Bates E R; Vahanian A; Armstrong P W; Criger D A; Topol E J; Holmes D R
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction.
Journal of the American College of Cardiology 2000;35(1):136-43.
2000: Topol E J
Acute myocardial infarction: thrombolysis.
Heart (British Cardiac Society) 2000;83(1):122-6.
2000: Crenshaw B S; Granger C B; Birnbaum Y; Pieper K S; Morris D C; Kleiman N S; Vahanian A; Califf R M; Topol E J
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators.
Circulation 2000;101(1):27-32.
2000: Kleiman N S; Tracy R P; Talley J D; Sigmon K; Joseph D; Topol E J; Califf R M; Kitt M; Ohman E M
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
Journal of thrombosis and thrombolysis 2000;9(1):5-12.
2000: Bhatt D L; Kapadia S R; Yadav J S; Topol E J
Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.
Cerebrovascular diseases (Basel, Switzerland) 2000;10 Suppl 5():34-40.
1999: Topol E J
New platelet glycoprotein IIb/IIIa inhibitor trials in percutaneous coronary intervention.
The Journal of invasive cardiology 1999;11 Suppl C():3C-6C.
1999: Topol E J; Mark D B; Lincoff A M; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot C F; Anderson K M; Califf R M
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Lancet 1999;354(9195):2019-24.
1999: Ohman E M; Armstrong P W; White H D; Granger C B; Wilcox R G; Weaver W D; Gibler W B; Stebbins A L; Cianciolo C; Califf R M; Topol E J
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries.
The American journal of cardiology 1999;84(11):1281-6.
1999: Marso S P; Lincoff A M; Ellis S G; Bhatt D L; Tanguay J F; Kleiman N S; Hammoud T; Booth J E; Sapp S K; Topol E J
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Circulation 1999;100(25):2477-84.
1999: Asher C R; Topol E J; Moliterno D J
Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes.
American heart journal 1999;138(6 Pt 1):1073-81.
1999: Topol E
ACE inhibitors still the drug of choice for heart failure--and more.
Lancet 1999;354(9192):1797.
1999: Cohen M G; Granger C B; Ohman E M; Stebbins A L; Grinfeld L R; Cagide A M; Elizari M V; Betriu A; Kong D F; Topol E J; Califf R M
Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1999;34(6):1729-37.
1999: Holmes D R; Berger P B; Hochman J S; Granger C B; Thompson T D; Califf R M; Vahanian A; Bates E R; Topol E J
Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation.
Circulation 1999;100(20):2067-73.
1999: Kong D F; Topol E J; Bittl J A; White H D; Théroux P; Hasselblad V; Califf R M
Clinical outcomes of bivalirudin for ischemic heart disease.
Circulation 1999;100(20):2049-53.
1999: Boersma E; Akkerhuis K M; Théroux P; Califf R M; Topol E J; Simoons M L
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Circulation 1999;100(20):2045-8.
1999: Steinhubl S R; Kottke-Marchant K; Moliterno D J; Rosenthal M L; Godfrey N K; Coller B S; Topol E J; Lincoff A M
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.
Circulation 1999;100(19):1977-82.
1999: Ellis S G; Guetta V; Miller D; Whitlow P L; Topol E J
Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from 10,907 lesions and proposal for new classification scheme.
Circulation 1999;100(19):1971-6.
1999: Gilchrist I C; Gardner L H; Muhlestein J B; Arnold A M; Lincoff A M; Califf R M; Tcheng J E; Topol E J
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience.
American heart journal 1999;138(5 Pt 1):976-82.
1999: Patel V B; Topol E J
The pathogenesis and spectrum of acute coronary syndromes: from plaque formation to thrombosis.
Cleveland Clinic journal of medicine 1999;66(9):561-71.
1999: Miller J M; Smalling R; Ohman E M; Bode C; Betriu A; Kleiman N S; Schildcrout J S; Bastos E; Topol E J; Califf R M
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries.
The American journal of cardiology 1999;84(7):779-84.
1999: Brener S; Topol E J
Logic and logistics: conundrum in reperfusion treatment for acute myocardial infarction.
Heart (British Cardiac Society) 1999;82(4):402-3.
1999: Marso S P; Mak K H; Topol E J
Diabetes mellitus: biological determinants of atherosclerosis and restenosis.
Seminars in interventional cardiology : SIIC 1999;4(3):129-43.
1999: Brener S J; Barr L A; Burchenal J E; Wolski K E; Effron M B; Topol E J
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial.
The American journal of cardiology 1999;84(6):728-30, A8.
1999: Lauer M S; Blackstone E H; Young J B; Topol E J
Cause of death in clinical research: time for a reassessment?
Journal of the American College of Cardiology 1999;34(3):618-20.
1999: Mahaffey K W; Granger C B; Sloan M A; Green C L; Gore J M; Weaver W D; White H D; Simoons M L; Barbash G I; Topol E J; Califf R M
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.
American heart journal 1999;138(3 Pt 1):493-9.
1999: Gassler J P; Topol E J
Reperfusion revisited: beyond TIMI 3 flow.
Clinical cardiology 1999;22(8 Suppl):IV20-9.
1999: Van De Werf F; Adgey J; Ardissino D; Armstrong P W; Aylward P; Barbash G; Betriu A; Binbrek A S; Califf R; Diaz R; Fanebust R; Fox K; Granger C; Heikkilä J; Husted S; Jansky P; Langer A; Lupi E; Maseri A; Meyer J; Mlczoch J; Mocceti D; Myburgh D; Oto A; Paolasso E; Pehrsson K; Seabra-Gomes R; Soares-Piegas L; Sùgrue D; Tendera M; Topol E; Toutouzas P; Vahanian A; Verheugt F; Wallentin L; White H
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Lancet 1999;354(9180):716-22.
1999: Simoons M L; van den Brand M; Lincoff M; Harrington R; van der Wieken R; Vahanian A; Rutsch W; Kootstra J; Boersma E; Califf R M; Topol E
Minimal myocardial damage during coronary intervention is associated with impaired outcome.
European heart journal 1999;20(15):1112-9.
1999: Lincoff A M; Califf R M; Moliterno D J; Ellis S G; Ducas J; Kramer J H; Kleiman N S; Cohen E A; Booth J E; Sapp S K; Cabot C F; Topol E J
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
The New England journal of medicine 1999;341(5):319-27.
1999: Hochman J S; Tamis J E; Thompson T D; Weaver W D; White H D; Van de Werf F; Aylward P; Topol E J; Califf R M
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators.
The New England journal of medicine 1999;341(4):226-32.
1999: Berger P B; Ellis S G; Holmes D R; Granger C B; Criger D A; Betriu A; Topol E J; Califf R M
Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial.
Circulation 1999;100(1):14-20.
1999: Hasdai D; Holmes D R; Califf R M; Thompson T D; Hochman J S; Pfisterer M; Topol E J
Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
American heart journal 1999;138(1 Pt 1):21-31.
1999: Steinhubl S R; Topol E J
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.
Journal of thrombosis and thrombolysis 1999;7(3):227-31.
1999: McClure M W; Berkowitz S D; Sparapani R; Tuttle R; Kleiman N S; Berdan L G; Lincoff A M; Deckers J; Diaz R; Karsch K R; Gretler D; Kitt M; Simoons M; Topol E J; Califf R M; Harrington R A
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
Circulation 1999;99(22):2892-900.
1999: Mahaffey K W; Harrington R A; Simoons M L; Granger C B; Graffagnino C; Alberts M J; Laskowitz D T; Miller J M; Sloan M A; Berdan L G; MacAulay C M; Lincoff A M; Deckers J; Topol E J; Califf R M
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Circulation 1999;99(18):2371-7.
1999: Alexander J H; Granger C B; Sadowski Z; Aylward P E; White H D; Thompson T D; Califf R M; Topol E J
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators.
American heart journal 1999;137(5):799-805.
1999: Califf R M; Stump D; Topol E J; Mark D B
Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
American heart journal 1999;137(5):S90-3.
1999: Horrigan M C; Malycky J L; Ellis S G; Topol E J; Nicolini F A
Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model.
International journal of cardiology 1999;68 Suppl 1():S85-91.
1999: Alexander J H; Harrington R A; Tuttle R H; Berdan L G; Lincoff A M; Deckers J W; Simoons M L; Guerci A; Hochman J S; Wilcox R G; Kitt M M; Eisenberg P R; Califf R M; Topol E J; Karsh K; Ruzyllo W; Stepinska J; Widimsky P; Boland J B; Armstrong P W
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
The American journal of cardiology 1999;83(8):1147-51.
1999: Lincoff A M; Tcheng J E; Califf R M; Kereiakes D J; Kelly T A; Timmis G C; Kleiman N S; Booth J E; Balog C; Cabot C F; Anderson K M; Weisman H F; Topol E J
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Circulation 1999;99(15):1951-8.
1999: Ellis S G; Miller D; Keys T F; Brown K; Ellert R; Howell G; Lincoff A M; Topol E J
Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results.
Journal of the American College of Cardiology 1999;33(5):1278-85.
1999: Marso S P; Ellis S G; Tuzcu M; Whitlow P L; Franco I; Raymond R E; Topol E J
The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics.
Journal of the American College of Cardiology 1999;33(5):1269-77.
1999: Hasdai D; Lerman A; Rihal C S; Criger D A; Garratt K N; Betriu A; White H D; Topol E J; Granger C B; Ellis S G; Califf R M; Holmes D R
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction.
American heart journal 1999;137(4 Pt 1):612-20.
1999: Narins C R; Miller D P; Califf R M; Topol E J
The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Journal of the American College of Cardiology 1999;33(3):647-53.
1999: Steinhubl S R; Tan W A; Foody J M; Topol E J
Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
JAMA : the journal of the American Medical Association 1999;281(9):806-10.
1999: Rabbani R; Topol E J
Strategies to achieve coronary arterial plaque stabilization.
Cardiovascular research 1999;41(2):402-17.
1999: Puma J A; Sketch M H; Thompson T D; Simes R J; Morris D C; White H D; Topol E J; Califf R M
Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy.
The American journal of cardiology 1999;83(4):482-7.
1999: Savonitto S; Ardissino D; Granger C B; Morando G; Prando M D; Mafrici A; Cavallini C; Melandri G; Thompson T D; Vahanian A; Ohman E M; Califf R M; Van de Werf F; Topol E J
Prognostic value of the admission electrocardiogram in acute coronary syndromes.
JAMA : the journal of the American Medical Association 1999;281(8):707-13.
1999: Berger P B; Tuttle R H; Holmes D R; Topol E J; Aylward P E; Horgan J H; Califf R M
One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial.
Circulation 1999;99(7):873-8.
1999: Holmes D R; White H D; Pieper K S; Ellis S G; Califf R M; Topol E J
Effect of age on outcome with primary angioplasty versus thrombolysis.
Journal of the American College of Cardiology 1999;33(2):412-9.
1999: Thel M C; Califf R M; Tcheng J E; Sigmon K N; Lincoff A M; Topol E J; Ellis S G
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.
American heart journal 1999;137(2):264-73.
1999: Harrington R A; Califf R M; Holmes D R; Pieper K S; Lincoff A M; Berdan L G; Thompson T D; Topol E J
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators.
American heart journal 1999;137(2):227-33.
1999: Hasdai D; Holmes D R; Topol E J; Berger P B; Criger D A; Hochman J S; Bates E R; Vahanian A; Armstrong P W; Wilcox R; Ohman E M; Califf R M
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
European heart journal 1999;20(2):128-35.
1999: Tardiff B E; Califf R M; Tcheng J E; Lincoff A M; Sigmon K N; Harrington R A; Mahaffey K W; Ohman E M; Teirstein P S; Blankenship J C; Kitt M M; Topol E J
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
Journal of the American College of Cardiology 1999;33(1):88-96.
1999: Topol E J; Byzova T V; Plow E F
Platelet GPIIb-IIIa blockers.
Lancet 1999;353(9148):227-31.
1999: Tung C Y; Granger C B; Sloan M A; Topol E J; Knight J D; Weaver W D; Mahaffey K W; White H; Clapp-Channing N; Simoons M L; Gore J M; Califf R M; Mark D B
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Circulation 1999;99(3):370-6.
1999: Kleiman N S; Granger C B; White H D; Armstrong P; Ardissino D; de Werf F V; Zoldeyhi P; Thompson T D; Califf R M; Topol E J
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion.
American heart journal 1999;137(1):12-23.
1998: Gibler W B; Wilcox R G; Bode C; Castaigne A D; Delooz H; Elich D; Fox K A; Kereiakes D J; Rupprecht H; Topol E J
Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
European journal of emergency medicine : official journal of the European Society for Emergency Medicine 1998;5(4):391-402.
1998: Simons G R; Sgarbossa E; Wagner G; Califf R M; Topol E J; Natale A
Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era.
Pacing and clinical electrophysiology : PACE 1998;21(12):2651-63.
1998: Mak K H; Kottke-Marchant K; Brooks L M; Topol E J
In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
Thrombosis and haemostasis 1998;80(6):989-93.
1998: Kong D F; Califf R M; Miller D P; Moliterno D J; White H D; Harrington R A; Tcheng J E; Lincoff A M; Hasselblad V; Topol E J
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation 1998;98(25):2829-35.
1998: Schwartz R S; Topol E J; Serruys P W; Sangiorgi G; Holmes D R
Artery size, neointima, and remodeling: time for some standards.
Journal of the American College of Cardiology 1998;32(7):2087-94.
1998: Alexander K P; Peterson E D; Granger C B; Casas A C; Van de Werf F; Armstrong P W; Guerci A; Topol E J; Califf R M
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial.
Journal of the American College of Cardiology 1998;32(7):2023-30.
1998: Newby K H; Thompson T; Stebbins A; Topol E J; Califf R M; Natale A
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators.
Circulation 1998;98(23):2567-73.
1998: Topol E J
Coronary-artery stents--gauging, gorging, and gouging.
The New England journal of medicine 1998;339(23):1702-4.
1998: Gibler W B; Wilcox R G; Bode C; Castaigne A D; Delooz H; Elich D; Fox K A; Kereiakes D J; Rupprecht H; Topol E J
Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
Annals of emergency medicine 1998;32(6):712-22.
1998: Marso S P; Topol E J
The paradoxical benefit of sulfonylurea agents in diabetics undergoing coronary revascularization.
European heart journal 1998;19(11):1601-3.
1998: Roe M T; Bowen T E; Topol E J
Management of non-Q-wave myocardial infarction.
The New England journal of medicine 1998;339(19):1396-7; author reply 1397-8.
1998: Ellis S G; Lincoff A M; Miller D; Tcheng J E; Kleiman N S; Kereiakes D; Califf R; Topol E J
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
Journal of the American College of Cardiology 1998;32(6):1619-23.
1998: Bhatt D L; Lincoff A M; Kereiakes D J; Tcheng J E; Simoons M L; van der Wieken L R; Godfrey N; Califf R M; Topol E J
Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.
The American journal of cardiology 1998;82(9):1105-6, A6.
1998: Zabel K M; Granger C B; Becker R C; Bovill E G; Hirsh J; Aylward P E; Topol E J; Califf R M
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
American heart journal 1998;136(5):868-76.
1998: Steinhubl S R; Lauer M S; Mukherjee D P; Moliterno D J; Lincoff A M; Ellis S G; Topol E J
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
Journal of the American College of Cardiology 1998;32(5):1366-70.
1998: Armstrong P W; Fu Y; Chang W C; Topol E J; Granger C B; Betriu A; Van de Werf F; Lee K L; Califf R M
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.
Circulation 1998;98(18):1860-8.
1998: Newby L K; Christenson R H; Ohman E M; Armstrong P W; Thompson T D; Lee K L; Hamm C W; Katus H A; Cianciolo C; Granger C B; Topol E J; Califf R M
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators.
Circulation 1998;98(18):1853-9.
1998: Topol E J
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
The American journal of cardiology 1998;82(8B):63P-68P.
1998: Topol E J; Serruys P W
Frontiers in interventional cardiology.
Circulation 1998;98(17):1802-20.
1998: Topol E J
The future of antithrombotic and antiplatelet therapy for ischemic heart disease.
American heart journal 1998;136(4 Pt 2 Su):S66-8.
1998: Benzaquen B S; Eisenberg M J; Challapalli R; Nguyen T; Brown K J; Topol E J
Correlates of in-hospital cost among patients undergoing abdominal aortic aneurysm repair.
American heart journal 1998;136(4 Pt 1):696-702.
1998: Anderson R D; Ohman E M; Holmes D R; Harrington R A; Barsness G W; Wildermann N M; Phillips H R; Topol E J; Califf R M
Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions.
Journal of the American College of Cardiology 1998;32(4):936-41.
1998: Sloan M A; Sila C A; Mahaffey K W; Granger C B; Longstreth W T; Koudstaal P; White H D; Gore J M; Simoons M L; Weaver W D; Green C L; Topol E J; Califf R M
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage.
Circulation 1998;98(14):1376-82.
1998: Topol E
Patient stratification and its predictive value for cardiac events.
European heart journal 1998;19 Suppl K():K5-7.
1998: Kereiakes D J; Kleiman N S; Ferguson J J; Masud A R; Broderick T M; Abbottsmith C W; Runyon J P; Anderson L C; Anders R J; Dreiling R J; Hantsbarger G L; Bryzinski B; Topol E J
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Circulation 1998;98(13):1268-78.
1998: Topol E J
Publication and promotion. Drafter and draftees.
Lancet 1998;352(9131):897-8.
1998: Pfisterer M; Cox J L; Granger C B; Brener S J; Naylor C D; Califf R M; van de Werf F; Stebbins A L; Lee K L; Topol E J; Armstrong P W
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1998;32(3):634-40.
1998: Serebruany V L; Gurbel P A; Shustov A R; Ohman E M; Topol E J
Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction.
American heart journal 1998;136(3):398-405.
1998: Gebel J M; Sila C A; Sloan M A; Granger C B; Weisenberger J P; Green C L; Topol E J; Mahaffey K W
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial.
Stroke; a journal of cerebral circulation 1998;29(9):1799-801.
1998: Brener S J; Barr L A; Burchenal J E; Katz S; George B S; Jones A A; Cohen E D; Gainey P C; White H J; Cheek H B; Moses J W; Moliterno D J; Effron M B; Topol E J
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
Circulation 1998;98(8):734-41.
1998: Topol E J
What role for catheter laboratories in unstable angina?
Lancet 1998;352(9127):500-1.
1998: Berkowitz S D; Sane D C; Sigmon K N; Shavender J H; Harrington R A; Tcheng J E; Topol E J; Califf R M
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
Journal of the American College of Cardiology 1998;32(2):311-9.
1998: Ghaffari S; Kereiakes D J; Lincoff A M; Kelly T A; Timmis G C; Kleiman N S; Ferguson J J; Miller D P; Califf R A; Topol E J
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
The American journal of cardiology 1998;82(1):7-12.
1998: Mandak J S; Blankenship J C; Gardner L H; Berkowitz S D; Aguirre F V; Sigmon K N; Timmis G C; Gilchrist I C; McIvor M; Resar J; Weiner B H; George B S; Talley J D; Lincoff A M; Tcheng J E; Califf R M; Topol E J
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Journal of the American College of Cardiology 1998;31(7):1518-24.
1998: Metz B K; White H D; Granger C B; Simes R J; Armstrong P W; Hirsh J; Fuster V; MacAulay C M; Califf R M; Topol E J
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Journal of the American College of Cardiology 1998;31(7):1493-8.
1998: Gurbel P A; Serebruany V L; Shustov A R; Bahr R D; Carpo C; Ohman E M; Topol E J
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
Journal of the American College of Cardiology 1998;31(7):1466-73.
1998: Brieger D B; Mak K H; Kottke-Marchant K; Topol E J
Heparin-induced thrombocytopenia.
Journal of the American College of Cardiology 1998;31(7):1449-59.
1998: Kleiman N S; Lincoff A M; Kereiakes D J; Miller D P; Aguirre F V; Anderson K M; Weisman H F; Califf R M; Topol E J
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Circulation 1998;97(19):1912-20.
1998: Hochrein J; Sun F; Pieper K S; Lee K L; Gates K B; Armstrong P W; Weaver W D; Goodman S G; Topol E J; Califf R M; Granger C B; Wagner G S
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries.
The American journal of cardiology 1998;81(9):1078-84.
1998: Ellis S G; Brown K J; Ellert R; Howell G L; Miller D P; Flowers N M; Ott P A; Keys T; Loop F D; Topol E J
Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications.
Journal of the American College of Cardiology 1998;31(6):1306-13.
1998: Ross A M; Coyne K S; Moreyra E; Reiner J S; Greenhouse S W; Walker P L; Simoons M L; Draoui Y C; Califf R M; Topol E J; Van de Werf F; Lundergan C F
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.
Circulation 1998;97(16):1549-56.
1998: Mak K H; Tan A T; Chan C; Koh T H; Topol E J
The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine.
Japanese circulation journal 1998;62(4):233-43.
1998: Narins C R; Holmes D R; Topol E J
A call for provisional stenting: the balloon is back!
Circulation 1998;97(13):1298-305.
1998: Motwani J G; Topol E J
Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention.
Circulation 1998;97(9):916-31.
1998: Kereiakes D J; Lincoff A M; Miller D P; Tcheng J E; Cabot C F; Anderson K M; Weisman H F; Califf R M; Topol E J
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
Circulation 1998;97(9):857-64.
1998: Christenson R H; Duh S H; Newby L K; Ohman E M; Califf R M; Granger C B; Peck S; Pieper K S; Armstrong P W; Katus H A; Topol E J
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators.
Clinical chemistry 1998;44(3):494-501.
1998: Gebel J M; Sila C A; Sloan M A; Granger C B; Mahaffey K W; Weisenberger J; Green C L; White H D; Gore J M; Weaver W D; Califf R M; Topol E J
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Stroke; a journal of cerebral circulation 1998;29(3):563-9.
1998: Granger C B; Becker R; Tracy R P; Califf R M; Topol E J; Pieper K S; Ross A M; Roth S; Lambrew C; Bovill E G
Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1998;31(3):497-505.
1998: Mahaffey K W; Granger C B; Sloan M A; Thompson T D; Gore J M; Weaver W D; White H D; Simoons M L; Barbash G I; Topol E J; Califf R M
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I.
Circulation 1998;97(8):757-64.
1998: Goodman S G; Langer A; Ross A M; Wildermann N M; Barbagelata A; Sgarbossa E B; Wagner G S; Granger C B; Califf R M; Topol E J; Simoons M L; Armstrong P W
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
Circulation 1998;97(5):444-50.
1998: Brieger D B; Mak K H; White H D; Kleiman N S; Miller D P; Vahanian A; Ross A M; Califf R M; Topol E J
Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries.
The American journal of cardiology 1998;81(3):282-7.
1998: Omoigui N A; Silver M J; Rybicki L A; Rosenthal M; Berdan L G; Pieper K; King S V; Califf R M; Topol E J
Influence of a randomized clinical trial on practice by participating investigators: lessons from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). CAVEAT I and II Investigators.
Journal of the American College of Cardiology 1998;31(2):265-72.
1998: Califf R M; Abdelmeguid A E; Kuntz R E; Popma J J; Davidson C J; Cohen E A; Kleiman N S; Mahaffey K W; Topol E J; Pepine C J; Lipicky R J; Granger C B; Harrington R A; Tardiff B E; Crenshaw B S; Bauman R P; Zuckerman B D; Chaitman B R; Bittl J A; Ohman E M
Myonecrosis after revascularization procedures.
Journal of the American College of Cardiology 1998;31(2):241-51.
1998: Blankenship J C; Hellkamp A S; Aguirre F V; Demko S L; Topol E J; Califf R M
Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.
The American journal of cardiology 1998;81(1):36-40.
1998: Serebruany V L; Gurbel P A; Shustov A R; Dalesandro M R; Gumbs C I; Grabletz L B; Bahr R D; Ohman E M; Topol E J
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Stroke; a journal of cerebral circulation 1998;29(1):235-8.
1998: Topol E J
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.
Circulation 1998;97(2):211-8.
1998: Sgarbossa E B; Pinski S L; Topol E J; Califf R M; Barbagelata A; Goodman S G; Gates K B; Granger C B; Miller D P; Underwood D A; Wagner G S
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1998;31(1):105-10.
1998: Betriu A; Califf R M; Bosch X; Guerci A; Stebbins A L; Barbagelata N A; Aylward P E; Vahanian A; Van de Werf F; Topol E J
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1998;31(1):94-102.
1998: Khan M M; Ellis S G; Aguirre F V; Weisman H F; Wildermann N M; Califf R M; Topol E J; Kleiman N S
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
Journal of the American College of Cardiology 1998;31(1):31-6.
1998: Gurbel P A; Serebruany V L; Shustov A R; Dalesandro M; Gumbs C I; Grablutz L B; Bahr R D; Ohman E M; Topol E J
Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis.
Coronary artery disease 1998;9(7):451-6.
1997: Narins C R; Topol E J
Cardiology. Attention shifts to the white clot.
Lancet 1997;350 Suppl 3():SIII2.
1997: Holmes D R; Topol E J
Cardiogenic shock: 'going to the mat'--is it needed and does it work?
European heart journal 1997;18(12):1839-40.
1997: Mahaffey K W; Granger C B; Toth C A; White H D; Stebbins A L; Barbash G I; Vahanian A; Topol E J; Califf R M
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1997;30(7):1606-10.
1997: Ohman E M; Califf R M; Topol E J
Trials in myocardial infarction.
Circulation 1997;96(10):3814-6.
1997: Pietilä K; Hermens W T; Harmoinen A; Baardman T; Pasternack A; Topol E J; Simoons M L
Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase.
The American journal of cardiology 1997;80(8):1075-7.
1997: Mak K H; Challapalli R; Eisenberg M J; Anderson K M; Califf R M; Topol E J
Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
The American journal of cardiology 1997;80(8):985-8.
1997: Topol E J
Validation for coronary stenting: a permanent implant for interventional cardiology.
European heart journal 1997;18(10):1525-6.
1997: Brieger D; Topol E
Local drug delivery systems and prevention of restenosis.
Cardiovascular research 1997;35(3):405-13.
1997: Belli G; Ellis S G; Topol E J
Stenting for ischemic heart disease.
Progress in cardiovascular diseases 1997;40(2):159-82.
1997: Lefkovits J; Topol E J
Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention.
Progress in cardiovascular diseases 1997;40(2):141-58.
1997: Christenson R H; Ohman E M; Topol E J; Peck S; Newby L K; Duh S H; Kereiakes D J; Worley S J; Alosozana G L; Wall T C; Califf R M
Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7.
Circulation 1997;96(6):1776-82.
1997: Gottsauner-Wolf M; Jang Y; Penn M S; Kaplan A; Ellis S G; Chisolm G M; Topol E J; Lincoff A M
Quantitative evaluation of local drug delivery using the InfusaSleeve catheter.
Catheterization and cardiovascular diagnosis 1997;42(1):102-8.
1997: Anderson R D; Ohman E M; Holmes D R; Col I; Stebbins A L; Bates E R; Stomel R J; Granger C B; Topol E J; Califf R M
Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1997;30(3):708-15.
1997: Steinhubl S R; Topol E J
Stenting for acute myocardial infarction.
Lancet 1997;350(9077):532-3.
1997: Brener S J; Loop F D; Lytle B W; Ellis S G; Cosgrove D M; Topol E J
A profile of candidates for repeat myocardial revascularization: implications for selection of treatment.
The Journal of thoracic and cardiovascular surgery 1997;114(2):153-61.
1997: Guetta V; Topol E J
Pacifying the infarct vessel.
Circulation 1997;96(3):713-5.
1997: Topol E J; Ferguson J J; Weisman H F; Tcheng J E; Ellis S G; Kleiman N S; Ivanhoe R J; Wang A L; Miller D P; Anderson K M; Califf R M
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
JAMA : the journal of the American Medical Association 1997;278(6):479-84.
1997: Crenshaw B S; Ward S R; Granger C B; Stebbins A L; Topol E J; Califf R M
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1997;30(2):406-13.
1997: Berger P B; Holmes D R; Stebbins A L; Bates E R; Califf R M; Topol E J
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
Circulation 1997;96(1):122-7.
1997: Migrino R Q; Young J B; Ellis S G; White H D; Lundergan C F; Miller D P; Granger C B; Ross A M; Califf R M; Topol E J
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators.
Circulation 1997;96(1):116-21.
1997: Simpfendorfer C; Kottke-Marchant K; Lowrie M; Anders R J; Burns D M; Miller D P; Cove C S; DeFranco A C; Ellis S G; Moliterno D J; Raymond R E; Sutton J M; Topol E J
First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
Circulation 1997;96(1):76-81.
1997: Mak K H; Moliterno D J; Granger C B; Miller D P; White H D; Wilcox R G; Califf R M; Topol E J
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1997;30(1):171-9.
1997: Lincoff A M; Califf R M; Anderson K M; Weisman H F; Aguirre F V; Kleiman N S; Harrington R A; Topol E J
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Journal of the American College of Cardiology 1997;30(1):149-56.
1997: Moliterno D J; Topol E J
Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction.
Thrombosis and haemostasis 1997;78(1):214-9.
1997: Moen E K; Asher C R; Miller D P; Weaver W D; White H D; Califf R M; Topol E J
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Journal of women's health / the official publication of the Society for the Advancement of Women's Health Research 1997;6(3):285-93.
1997: O'Connor C M; Hathaway W R; Bates E R; Leimberger J D; Sigmon K N; Kereiakes D J; George B S; Samaha J K; Abbottsmith C W; Candela R J; Topol E J; Califf R M
Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model.
American heart journal 1997;133(6):663-73.
1997: Califf R M; Woodlief L H; Harrell F E; Lee K L; White H D; Guerci A; Barbash G I; Simes R J; Weaver W D; Simoons M L; Topol E J
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators.
American heart journal 1997;133(6):630-9.
1997: Ellis S G; Brener S J; DeLuca S; Tuzcu E M; Raymond R E; Whitlow P L; Topol E J
Late myocardial ischemic events after saphenous vein graft intervention--importance of initially "nonsignificant" vein graft lesions.
The American journal of cardiology 1997;79(11):1460-4.
1997: Berkowitz S D; Granger C B; Pieper K S; Lee K L; Gore J M; Simoons M; Armstrong P W; Topol E J; Califf R M
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
Circulation 1997;95(11):2508-16.
1997: Forrester J S; Topol E J; Abele J E; Holmes D R; Skorton D J
28th Bethesda Conference. Task Force 5: Assessment, approval, and regulation of new technology.
Journal of the American College of Cardiology 1997;29(6):1171-9.
1997: Mak K H; Topol E J
Clinical trials to prevent restenosis after percutaneous coronary revascularization.
Annals of the New York Academy of Sciences 1997;811():255-84; discussion 284-8.
1997: Eisenberg M J; Califf R M; Cohen E A; Adelman A G; Mark D B; Topol E J
Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators.
The American journal of cardiology 1997;79(7):867-72.
1997: Lincoff A M; Furst J G; Ellis S G; Tuch R J; Topol E J
Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.
Journal of the American College of Cardiology 1997;29(4):808-16.
1997: Levine G N; Jacobs A K; Keeler G P; Whitlow P L; Berdan L G; Leya F; Topol E J; Califf R M
Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial.
The American journal of cardiology 1997;79(6):748-55.
1997: Ward S R; Sutton J M; Pieper K S; Schwaiger M; Califf R M; Topol E J
Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
The American journal of cardiology 1997;79(5):539-44.
1997: Hannan E L; Racz M; Ryan T J; McCallister B D; Johnson L W; Arani D T; Guerci A D; Sosa J; Topol E J
Coronary angioplasty volume-outcome relationships for hospitals and cardiologists.
JAMA : the journal of the American Medical Association 1997;277(11):892-8.
1997: Gottsauner-Wolf M; Jang Y; Lincoff A M; Cohen J L; Labhasetwar V; Poptic E J; Forudi F; Guzman L A; DiCorleto P E; Levy R J; Topol E J; Ellis S G
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model.
American heart journal 1997;133(3):329-34.
1997: Barbagelata N A; Granger C B; Oqueli E; Suárez L D; Borruel M; Topol E J; Califf R M
TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
American heart journal 1997;133(3):273-82.
1997: Topol E J; Califf R M; Van de Werf F; Simoons M; Hampton J; Lee K L; White H; Simes J; Armstrong P W
Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group.
Circulation 1997;95(4):1072-82.
1997: Ohman E M; Kleiman N S; Gacioch G; Worley S J; Navetta F I; Talley J D; Anderson H V; Ellis S G; Cohen M D; Spriggs D; Miller M; Kereiakes D; Yakubov S; Kitt M M; Sigmon K N; Califf R M; Krucoff M W; Topol E J
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
Circulation 1997;95(4):846-54.
1997: Lincoff A M; Tcheng J E; Califf R M; Bass T; Popma J J; Teirstein P S; Kleiman N S; Hattel L J; Anderson H V; Ferguson J J; Cabot C F; Anderson K M; Berdan L G; Musco M H; Weisman H F; Topol E J
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
The American journal of cardiology 1997;79(3):286-91.
1997: Tardiff B E; Califf R M; Morris D; Bates E; Woodlief L H; Lee K L; Green C; Rutsch W; Betriu A; Aylward P E; Topol E J
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1997;29(2):240-9.
1997: Brener S J; Ellis S G; Apperson-Hansen C; Leon M B; Topol E J
Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years.
The American journal of cardiology 1997;79(1):13-8.
1997: Topol E J
Reperfusion for acute myocardial infarction: 1997 and beyond.
Cleveland Clinic journal of medicine 1997;64(1):9-12.
1997: Holmes D R; Califf R M; Van de Werf F; Berger P B; Bates E R; Simoons M L; White H D; Thompson T D; Topol E J
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial.
Lancet 1997;349(9045):75-8.
1997: Woodfield S L; Lundergan C F; Reiner J S; Thompson M A; Rohrbeck S C; Deychak Y; Smith J O; Burton J R; McCarthy W F; Califf R M; White H D; Weaver W D; Topol E J; Ross A M
Gender and acute myocardial infarction: is there a different response to thrombolysis?
Journal of the American College of Cardiology 1997;29(1):35-42.
1996: Abdelmeguid A E; Topol E J
The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures.
Circulation 1996;94(12):3369-75.
1996: Labinaz M; Sketch M H; Stebbins A L; DeFranco A C; Holmes D R; Kleiman N S; Betriu A; Rutsch W R; Vahanian A; Topol E J; Califf R M
Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
The American journal of cardiology 1996;78(12):1338-44.
1996: Rashid J; Eisenberg M J; Topol E J
Cocaine-induced aortic dissection.
American heart journal 1996;132(6):1301-4.
1996: Aylward P E; Wilcox R G; Horgan J H; White H D; Granger C B; Califf R M; Topol E J
Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
Annals of internal medicine 1996;125(11):891-900.
1996: Lefkovits J; Malycky J L; Rao J S; Hart C E; Plow E F; Topol E J; Nicolini F A
Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
Journal of the American College of Cardiology 1996;28(7):1858-65.
1996: Woodfield S L; Lundergan C F; Reiner J S; Greenhouse S W; Thompson M A; Rohrbeck S C; Deychak Y; Simoons M L; Califf R M; Topol E J; Ross A M
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.
Journal of the American College of Cardiology 1996;28(7):1661-9.
1996: Le Breton H; Plow E F; Topol E J
Role of platelets in restenosis after percutaneous coronary revascularization.
Journal of the American College of Cardiology 1996;28(7):1643-51.
1996: Rao A K; Sun L; Chesebro J H; Fuster V; Harrington R A; Schwartz D; Gallo P; Matos D; Topol E J
Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Circulation 1996;94(10):2389-95.
1996: Brener S J; Leya F S; Apperson-Hansen C; Cowley M J; Califf R M; Topol E J
A comparison of debulking versus dilatation of bifurcation coronary arterial narrowings (from the CAVEAT I Trial). Coronary Angioplasty Versus Excisional Atherectomy Trial-I.
The American journal of cardiology 1996;78(9):1039-41.
1996: Schulman S P; Goldschmidt-Clermont P J; Topol E J; Califf R M; Navetta F I; Willerson J T; Chandra N C; Guerci A D; Ferguson J J; Harrington R A; Lincoff A M; Yakubov S J; Bray P F; Bahr R D; Wolfe C L; Yock P G; Anderson H V; Nygaard T W; Mason S J; Effron M B; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt M M; Gerstenblith G
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Circulation 1996;94(9):2083-9.
1996: O'Brien J E; Peterson E D; Keeler G P; Berdan L G; Ohman E M; Faxon D P; Jacobs A K; Topol E J; Califf R M
Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions.
Journal of the American College of Cardiology 1996;28(5):1111-8.
1996: Horrigan M C; MacIsaac A I; Nicolini F A; Vince D G; Lee P; Ellis S G; Topol E J
Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model.
Circulation 1996;94(8):1927-33.
1996: White H D; Barbash G I; Califf R M; Simes R J; Granger C B; Weaver W D; Kleiman N S; Aylward P E; Gore J M; Vahanian A; Lee K L; Ross A M; Topol E J
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
Circulation 1996;94(8):1826-33.
1996: Ohman E M; Armstrong P W; Christenson R H; Granger C B; Katus H A; Hamm C W; O'Hanesian M A; Wagner G S; Kleiman N S; Harrell F E; Califf R M; Topol E J
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators.
The New England journal of medicine 1996;335(18):1333-41.
1996: van der Giessen W J; Lincoff A M; Schwartz R S; van Beusekom H M; Serruys P W; Holmes D R; Ellis S G; Topol E J
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries.
Circulation 1996;94(7):1690-7.
1996: Abdelmeguid A E; Topol E J; Whitlow P L; Sapp S K; Ellis S G
Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions.
Circulation 1996;94(7):1528-36.
1996: Lefkovits J; Blankenship J C; Anderson K M; Stoner G L; Talley J D; Worley S J; Weisman H F; Califf R M; Topol E J
Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
Journal of the American College of Cardiology 1996;28(4):849-55.
1996: Rosenschein U; Topol E J
Uncoupling clinical outcomes and coronary angiography: a review and perspective of recent trials in coronary artery disease.
American heart journal 1996;132(4):910-20.
1996: Pilote L; Miller D P; Califf R M; Rao J S; Weaver W D; Topol E J
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction.
The New England journal of medicine 1996;335(16):1198-205.
1996: Topol E J
Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction.
European heart journal 1996;17 Suppl E():42-8.
1996: Topol E J
Treatment of acute myocardial infarction: in which patients should primary percutaneous transluminal coronary angioplasty be preferred to thrombolysis?
Cardiologia (Rome, Italy) 1996;41(9):843-7.
1996: Mak K H; Eisenberg M J; Plante S; Strauss B H; Arheart K L; Topol E J
Absence of increased in-hospital complications with reused balloon catheters.
The American journal of cardiology 1996;78(6):717-9.
1996: Guzman L A; Labhasetwar V; Song C; Jang Y; Lincoff A M; Levy R; Topol E J
Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty.
Circulation 1996;94(6):1441-8.
1996: Califf R M; White H D; Van de Werf F; Sadowski Z; Armstrong P W; Vahanian A; Simoons M L; Simes R J; Lee K L; Topol E J
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.
Circulation 1996;94(6):1233-8.
1996: Holmes D R; Garratt K N; Isner J M; Kearney M; Berdan L G; Schwartz R S; Califf R M; Topol E J
Effect of subintimal resection on initial outcome and restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary atherectomy. A report from the CAVEAT I and II investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial.
Journal of the American College of Cardiology 1996;28(3):645-51.
1996: Peterson E D; Hathaway W R; Zabel K M; Pieper K S; Granger C B; Wagner G S; Topol E J; Bates E R; Simoons M L; Califf R M
Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients.
Journal of the American College of Cardiology 1996;28(2):305-12.
1996: Mark D B; Talley J D; Topol E J; Bowman L; Lam L C; Anderson K M; Jollis J G; Cleman M W; Lee K L; Aversano T; Untereker W J; Davidson-Ray L; Califf R M
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Circulation 1996;94(4):629-35.
1996: Mak K H; Eisenberg M J; Eccleston D S; Brown K J; Ellis S G; Topol E J
Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty.
Journal of the American College of Cardiology 1996;28(1):106-11.
1996: Topol E J
Eric Jeffrey Topol: a conversation with the editor.
The American journal of cardiology 1996;78(1):72-81.
1996: Migrino R Q; Moliterno D J; Topol E J
Preinfarction angina.
The New England journal of medicine 1996;335(1):59; author reply 60-1.
1996: Challapalli R; Lefkovits J; Topol E J
Clinical trials of recombinant hirudin in acute coronary syndromes.
Coronary artery disease 1996;7(6):429-37.
1996: Abdelmeguid A E; Ellis S G; Sapp S K; Whitlow P L; Topol E J
Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions.
American heart journal 1996;131(6):1097-105.
1996: Newby L K; Rutsch W R; Califf R M; Simoons M L; Aylward P E; Armstrong P W; Woodlief L H; Lee K L; Topol E J; Van de Werf F
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.
Journal of the American College of Cardiology 1996;27(7):1646-55.
1996: Almony G T; Lefkovits J; Topol E J
Antiplatelet and anticoagulant use after myocardial infarction.
Clinical cardiology 1996;19(5):357-65.
1996: Gottsauner-Wolf M; Moliterno D J; Lincoff A M; Topol E J
Restenosis--an open file.
Clinical cardiology 1996;19(5):347-56.
1996: Lefkovits J; Topol E J
The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
Cleveland Clinic journal of medicine 1996;63(3):181-9.
1996: Lefkovits J; Ivanhoe R J; Califf R M; Bergelson B A; Anderson K M; Stoner G L; Weisman H F; Topol E J
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
The American journal of cardiology 1996;77(12):1045-51.
1996: Moliterno D J; Topol E J
Another step toward resolving the contrast controversy.
Journal of the American College of Cardiology 1996;27(6):1387-9.
1996: Langer A; Goodman S G; Topol E J; Charlesworth A; Skene A M; Wilcox R G; Armstrong P W
Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators)
Journal of the American College of Cardiology 1996;27(6):1327-32.
1996: Redlitz A; Nicolini F A; Malycky J L; Topol E J; Plow E F
Inducible carboxypeptidase activity. A role in clot lysis in vivo.
Circulation 1996;93(7):1328-30.
1996: Vogel R A; Topol E J
Practice guidelines and physician scorecards: grading the graders.
Cleveland Clinic journal of medicine 1996;63(2):124-8.
1996: Newby L K; Califf R M; Guerci A; Weaver W D; Col J; Horgan J H; Mark D B; Stebbins A; Van de Werf F; Gore J M; Topol E J
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial.
Journal of the American College of Cardiology 1996;27(3):625-32.
1996: Mak K-H; Eisenberg M J; Eccleston D S; Cornhill J F; Topol E J
Reuse of coronary angioplasty equipment: technical and clinical issues.
American heart journal 1996;131(3):624-30.
1996: Weaver W D; White H D; Wilcox R G; Aylward P E; Morris D; Guerci A; Ohman E M; Barbash G I; Betriu A; Sadowski Z; Topol E J; Califf R M
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
JAMA : the journal of the American Medical Association 1996;275(10):777-82.
1996: Granger C B; Hirsch J; Califf R M; Col J; White H D; Betriu A; Woodlief L H; Lee K L; Bovill E G; Simes R J; Topol E J
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
Circulation 1996;93(5):870-8.
1996: LeBreton H; Topol E; Plow E F
Evidence for a pivotal role of platelets in vascular reocclusion and restenosis.
Cardiovascular research 1996;31(2):235-6.
1996: Muller D W; Gordon D; Topol E J; Levy R J; Golomb G
Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting.
American heart journal 1996;131(2):211-8.
1996: Ellis S G; Omoigui N; Bittl J A; Lincoff M; Wolfe M W; Howell G; Topol E J
Analysis and comparison of operator-specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures.
Circulation 1996;93(3):431-9.
1996: Sgarbossa E B; Pinski S L; Barbagelata A; Underwood D A; Gates K B; Topol E J; Califf R M; Wagner G S
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
The New England journal of medicine 1996;334(8):481-7.
1996: Nicolini F A; Lee P; Malycky J L; Lefkovits J; Kottke-Marchant K; Plow E F; Topol E J
Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1996;7(1):39-48.
1996: Lefkovits J; Topol E J
Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease.
European heart journal 1996;17(1):9-18.
1996: Omoigui N A; Miller D P; Brown K J; Annan K; Cosgrove D; Lytle B; Loop F; Topol E J
Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes.
Circulation 1996;93(1):27-33.
1996: Metz B K; Topol E J
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1996;50(6-7):243-53.
1995: Eccleston D; Topol E J
Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis.
Coronary artery disease 1995;6(12):947-55.
1995: Karnash S L; Granger C B; White H D; Woodlief L H; Topol E J; Califf R M
Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial.
Journal of the American College of Cardiology 1995;26(7):1651-6.
1995: Silver M J; Young J; Topol E J
Amiodarone in congestive heart failure.
The New England journal of medicine 1995;333(24):1639-40; author reply 1640-1.
1995: Califf R M; Lincoff A M; Tcheng J E; Topol E J
An overview of the results of the EPIC trial.
European heart journal 1995;16 Suppl L():43-9.
1995: Holmes D R; Simpson J B; Berdan L G; Gottlieb R S; Leya F; Keeler G P; Califf R M; Topol E J
Abrupt closure: the CAVEAT I experience. Coronary Angioplasty Versus Excisional Atherectomy Trial.
Journal of the American College of Cardiology 1995;26(6):1494-500.
1995: Barbash G I; Reiner J; White H D; Wilcox R G; Armstrong P W; Sadowski Z; Morris D; Aylward P; Woodlief L H; Topol E J
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1995;26(5):1222-9.
1995: Jang Y; Guzman L A; Lincoff A M; Gottsauner-Wolf M; Forudi F; Hart C E; Courtman D W; Ezban M; Ellis S G; Topol E J
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.
Circulation 1995;92(10):3041-50.
1995: Gore J M; Granger C B; Simoons M L; Sloan M A; Weaver W D; White H D; Barbash G I; Van de Werf F; Aylward P E; Topol E J
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.
Circulation 1995;92(10):2811-8.
1995: Barbagelata A; Granger C B; Topol E J; Worley S J; Kereiakes D J; George B S; Ohman E M; Leimberger J D; Mark D B; Califf R M
Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group.
The American journal of cardiology 1995;76(14):1007-13.
1995: Abdel-Meguid A E; Whitlow P L; Simpfendorfer C; Sapp S K; Franco I; Ellis S G; Topol E J
Percutaneous revascularization of ostial saphenous vein graft stenoses.
Journal of the American College of Cardiology 1995;26(4):955-60.
1995: Omoigui N A; Califf R M; Pieper K; Keeler G; O'Hanesian M A; Berdan L G; Mark D B; Talley J D; Topol E J
Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I).
Journal of the American College of Cardiology 1995;26(4):922-30.
1995: Topol E J; Nissen S E
Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease.
Circulation 1995;92(8):2333-42.
1995: Guzman L A; Forudi F; Villa A E; Topol E J
Role of leukocytes in neointimal formation after balloon angioplasty in the rabbit atherosclerotic model.
Coronary artery disease 1995;6(9):693-701.
1995: Topol E J
Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors.
American heart journal 1995;130(3 Pt 2):666-72.
1995: Holmes D R; Bates E R; Kleiman N S; Sadowski Z; Horgan J H; Morris D C; Califf R M; Berger P B; Topol E J
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1995;26(3):668-74.
1995: Van de Werf F; Califf R M; Armstrong P W; Bates E R; Ross A M; Kleinman N S; Topol E J
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
European heart journal 1995;16(8):1024-6.
1995: Ellis S G; Miller D P; Brown K J; Omoigui N; Howell G L; Kutner M; Topol E J
In-hospital cost of percutaneous coronary revascularization. Critical determinants and implications.
Circulation 1995;92(4):741-7.
1995: Lefkovits J; Holmes D R; Califf R M; Safian R D; Pieper K; Keeler G; Topol E J
Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial.
Circulation 1995;92(4):734-40.
1995: Pilote L; Califf R M; Sapp S; Miller D P; Mark D B; Weaver W D; Gore J M; Armstrong P W; Ohman E M; Topol E J
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
The New England journal of medicine 1995;333(9):565-72.
1995: Topol E J
The stentor and the sea change.
The American journal of cardiology 1995;76(4):307-8.
1995: Horrigan M C; Topol E J
Direct angioplasty in acute myocardial infarction. State of the art and current controversies.
Cardiology clinics 1995;13(3):321-38.
1995: Silver M J; Sutton J M; Hook S; Lee P; Malycky J L; Phillips M L; Ellis S G; Topol E J; Nicolini F A
Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model.
Circulation 1995;92(3):492-9.
1995: Belli G; Topol E J
Reperfusion and antithrombotic strategies for acute MI.
Contemporary internal medicine 1995;7(7):31-8, 43-5.
1995: Lefkovits J; Topol E J
Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
Current opinion in cardiology 1995;10(4):420-6.
1995: Omoigui N A; Topol E J
Observational versus randomized medical device testing before and after market approval--the atherectomy-versus-angioplasty controversy.
Controlled clinical trials 1995;16(3):143-9.
1995: Aguirre F V; Topol E J; Ferguson J J; Anderson K; Blankenship J C; Heuser R R; Sigmon K; Taylor M; Gottlieb R; Hanovich G
Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.
Circulation 1995;91(12):2882-90.
1995: Holmes D R; Califf R M; Topol E J
Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
Journal of the American College of Cardiology 1995;25(7 Suppl):10S-17S.
1995: Christenson R H; Ohman E M; Topol E J; O'Hanesian M A; Sigmon K N; Duh S H; Kereiakes D; Worley S J; George B S; Pizzo C K
Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group.
Clinical chemistry 1995;41(6 Pt 1):844-52.
1995: Topol E J; Block P C; Holmes D R; Klinke W P; Brinker J A
Readiness for the scorecard era in cardiovascular medicine.
The American journal of cardiology 1995;75(16):1170-3.
1995: Abdelmeguid A E; Whitlow P L; Sapp S K; Ellis S G; Topol E J
Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure.
Circulation 1995;91(11):2733-41.
1995: Lefkovits J; Plow E F; Topol E J
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.
The New England journal of medicine 1995;332(23):1553-9.
1995: Van de Werf F; Topol E J; Lee K L; Woodlief L H; Granger C B; Armstrong P W; Barbash G I; Hampton J R; Guerci A; Simes R J
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
JAMA : the journal of the American Medical Association 1995;273(20):1586-91.
1995: Lincoff A M; Topol E J; Califf R M; Sigmon K N; Lee K L; Ohman E M; Rosenschein U; Ellis S G
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
The American journal of cardiology 1995;75(14):871-6.
1995: Ellis S G; Cowley M J; Whitlow P L; Vandormael M; Lincoff A M; DiSciascio G; Dean L S; Topol E J
Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) Group.
Journal of the American College of Cardiology 1995;25(5):1137-42.
1995: Becker R C; Charlesworth A; Wilcox R G; Hampton J; Skene A; Gore J M; Topol E J
Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.
Journal of the American College of Cardiology 1995;25(5):1063-8.
1995: Holmes D R; Topol E J; Califf R M; Berdan L G; Leya F; Berger P B; Whitlow P L; Safian R D; Adelman A G; Kellett M A
A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators.
Circulation 1995;91(7):1966-74.
1995: Simes R J; Topol E J; Holmes D R; White H D; Rutsch W R; Vahanian A; Simoons M L; Morris D; Betriu A; Califf R M
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Circulation 1995;91(7):1923-8.
1995: Villa A E; Guzman L A; Poptic E J; Labhasetwar V; D'Souza S; Farrell C L; Plow E F; Levy R J; DiCorleto P E; Topol E J
Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury.
Circulation research 1995;76(4):505-13.
1995: DeLuca S A; Korcuska L A; Oberstar B H; Rosenthal M L; Welsh P A; Topol E J
Are we promoting true informed consent in cardiovascular clinical trials?
The Journal of cardiovascular nursing 1995;9(3):54-61.
1995: Elliott J M; Berdan L G; Holmes D R; Isner J M; King S B; Keeler G P; Kearney M; Califf R M; Topol E J
One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I)
Circulation 1995;91(8):2158-66.
1995: Moliterno D J; Califf R M; Aguirre F V; Anderson K; Sigmon K N; Weisman H F; Topol E J
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
The American journal of cardiology 1995;75(8):559-62.
1995: Lee K L; Woodlief L H; Topol E J; Weaver W D; Betriu A; Col J; Simoons M; Aylward P; Van de Werf F; Califf R M
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators.
Circulation 1995;91(6):1659-68.
1995: Topol E J
Novel antithrombotic approaches to coronary artery disease.
The American journal of cardiology 1995;75(6):27B-33B.
1995: Gersh B J; Topol E J
Angioplasty or thrombolysis in acute myocardial infarction: dilate or dissolve?
Cleveland Clinic journal of medicine 1995;62(1):15-9.
1995: Grines C L; Topol E J; O'Neill W W; George B S; Kereiakes D; Phillips H R; Leimberger J D; Woodlief L H; Califf R M
Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.
Circulation 1995;91(2):298-303.
1994: Boehrer J D; Kereiakes D J; Navetta F I; Califf R M; Topol E J
Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications.
The American journal of cardiology 1994;74(11):1166-70.
1994: Jang Y; Lincoff A M; Plow E F; Topol E J
Cell adhesion molecules in coronary artery disease.
Journal of the American College of Cardiology 1994;24(7):1591-601.
1994: Savage M P; Fischman D L; Schatz R A; Teirstein P S; Leon M B; Baim D; Ellis S G; Topol E J; Hirshfeld J W; Cleman M W
Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. Palmaz-Schatz Stent Study Group.
Journal of the American College of Cardiology 1994;24(5):1207-12.
1994: MacIsaac A I; Ellis S G; Muller D W; Topol E J; Whitlow P L
Comparison of three coronary stents: clinical and angiographic outcome after elective placement in 134 consecutive patients.
Catheterization and cardiovascular diagnosis 1994;33(3):199-204.
1994: Domanski M J; Topol E J
Cardiogenic shock: current understandings and future research directions.
The American journal of cardiology 1994;74(7):724-6.
1994: Mark D B; Naylor C D; Hlatky M A; Califf R M; Topol E J; Granger C B; Knight J D; Nelson C L; Lee K L; Clapp-Channing N E
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States.
The New England journal of medicine 1994;331(17):1130-5.
1994: Topol E J
Eric J. Topol, MD: how to manage patients with unstable angina. Interview by Richard R. Kerr and Ray W. Gifford, JR., MD.
Geriatrics 1994;49(10):49-54.
1994: Lincoff A M; Topol E J; Ellis S G
Local drug delivery for the prevention of restenosis. Fact, fancy, and future.
Circulation 1994;90(4):2070-84.
1994: Tcheng J E; Ellis S G; George B S; Kereiakes D J; Kleiman N S; Talley J D; Wang A L; Weisman H F; Califf R M; Topol E J
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
Circulation 1994;90(4):1757-64.
1994: Lefkovits J; Topol E J
Direct thrombin inhibitors in cardiovascular medicine.
Circulation 1994;90(3):1522-36.
1994: Faxon D P; Spiro T E; Minor S; Coté G; Douglas J; Gottlieb R; Califf R; Dorosti K; Topol E; Gordon J B
Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
Circulation 1994;90(2):908-14.
1994: Steinberg J S; Hochman J S; Morgan C D; Dorian P; Naylor C D; Theroux P; Topol E J; Armstrong P W
Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.
Circulation 1994;90(2):746-52.
1994: Holmes D R; Topol E J; Adelman A G; Cohen E A; Califf R M
Randomized trials of directional coronary atherectomy: implications for clinical practice and future investigation.
Journal of the American College of Cardiology 1994;24(2):431-9.
1994: Topol E J
Caveats about elective coronary stenting.
The New England journal of medicine 1994;331(8):539-41.
1994: Topol E J; Califf R M; Lee K L
More on the GUSTO trial.
The New England journal of medicine 1994;331(4):277-8.
1994: Brown D L; MacIsaac A I; Topol E J
Pulmonary hemorrhage after intracoronary stent placement.
Journal of the American College of Cardiology 1994;24(1):91-4.
1994: Ellis S G; Lincoff A M; George B S; Kereiakes D J; Ohman E M; Krucoff M W; Califf R M; Topol E J
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
Coronary artery disease 1994;5(7):611-5.
1994: Lee K L; Califf R M; Topol E J
The last word on GUSTO, for now.
Annals of internal medicine 1994;120(11):970.
1994: Paranandi S N; Topol E J
Contemporary clinical trials of restenosis.
The Journal of invasive cardiology 1994;6(4):109-24.
1994: Lee K L; Califf R M; Simes J; Van de Werf F; Topol E J
Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Annals of internal medicine 1994;120(10):876-81; discussion 882-5.
1994: Nicolini F A; Lee P; Rios G; Kottke-Marchant K; Topol E J
Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
Circulation 1994;89(4):1802-9.
1994: Topol E J; Fuster V; Harrington R A; Califf R M; Kleiman N S; Kereiakes D J; Cohen M; Chapekis A; Gold H K; Tannenbaum M A
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Circulation 1994;89(4):1557-66.
1994: Lefkovits J; Topol E J
Future directions in thrombolysis for myocardial infarction: what are the unanswered questions?
Coronary artery disease 1994;5(4):306-16.
1994: Topol E J; Califf R M; Weisman H F; Ellis S G; Tcheng J E; Worley S; Ivanhoe R; George B S; Fintel D; Weston M
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
Lancet 1994;343(8902):881-6.
1994: Sgarbossa E B; Topol E J
Semantic ambiguity, the "non-" nosology and myocardial infarction.
Journal of clinical epidemiology 1994;47(4):441-6.
1994: Hicks R J; Melon P; Kalff V; Wolfe E; Dick R J; Popma J J; Topol E; Schwaiger M
Metabolic imaging by positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial function after reperfusion.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 1994;1(2 Pt 1):124-37.
1994: Holmes D R; Topol E J
Dilate or debulk?
Cleveland Clinic journal of medicine 1994;61(2):124-6.
1994: Rosenschein U; Ellis S G; Haudenschild C C; Yakubov S J; Muller D W; Dick R J; Topol E J
Comparison of histopathologic coronary lesions obtained from directional atherectomy in stable angina versus acute coronary syndromes.
The American journal of cardiology 1994;73(7):508-10.
1994: Villa A E; Guzman L A; Chen W; Golomb G; Levy R J; Topol E J
Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty.
The Journal of clinical investigation 1994;93(3):1243-9.
1994: Sutton J M; Ellis S G; Roubin G S; Pinkerton C A; King S B; Raizner A E; Holmes D R; Kereiakes D J; Topol E J
Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group.
Circulation 1994;89(3):1126-37.
1994: Harrington R A; Sane D C; Califf R M; Sigmon K N; Abbottsmith C W; Candela R J; Lee K L; Topol E J
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Journal of the American College of Cardiology 1994;23(4):891-8.
1994: Ellis S G; Popma J J; Buchbinder M; Franco I; Leon M B; Kent K M; Pichard A D; Satler L F; Topol E J; Whitlow P L
Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty.
Circulation 1994;89(2):882-92.
1994: Omoigui N; Topol E
On-site cardiac catheterization facilities and the use of coronary angiography after myocardial infarction.
The New England journal of medicine 1994;330(4):289; author reply 290.
1994: Topol E J; Califf R M
Scorecard cardiovascular medicine. Its impact and future directions.
Annals of internal medicine 1994;120(1):65-70.
1993: Topol E J
Validation of the early open infarct vessel hypothesis.
The American journal of cardiology 1993;72(19):40G-45G.
1993: Lincoff A M; Califf R M; Ellis S G; Sigmon K N; Lee K L; Leimberger J D; Topol E J
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Journal of the American College of Cardiology 1993;22(7):1780-7.
1993: Topol E J
Breaking the thrombolytic gridlock: insights from the GUSTO trial.
Cleveland Clinic journal of medicine 1993;60(6):445-7.
1993: Nath F C; Muller D W; Rosenschein U; Ellis S G; Topol E J
Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
The Canadian journal of cardiology 1993;9(9):797-801.
1993: Brown D L; Topol E J
Stroke complicating percutaneous coronary revascularization.
The American journal of cardiology 1993;72(15):1207-9.
1993: Bernardi M M; Califf R M; Kleiman N; Ellis S G; Topol E J
Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group.
The American journal of cardiology 1993;72(15):1121-5.
1993: Cowley M J; Vandermael M; Topol E J; Whitlow P L; Dean L S; Bulle T M; Ellis S G
Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty? Multivessel Angioplasty Prognosis Study (MAPS) Group.
Journal of the American College of Cardiology 1993;22(5):1289-97.
1993: Ohman E M; Topol E J; Califf R M; Bates E R; Ellis S G; Kereiakes D J; George B S; Samaha J K; Kline E; Sigmon K N
An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group.
Coronary artery disease 1993;4(11):957-64.
1993: Topol E J; Califf R M; Lee K L
The irony of biased editors who write editorials. GUSTO Investigators.
The British journal of clinical practice 1993;47(6):283-4.
1993: Baim D S; Hinohara T; Holmes D; Topol E; Pinkerton C; King S B; Whitlow P; Kereiakes D; Farley B; Simpson J B
Results of directional coronary atherectomy during multicenter preapproval testing. The US Directional Coronary Atherectomy Investigator Group.
The American journal of cardiology 1993;72(13):6E-11E.
1993: MacIsaac A I; Thomas J D; Topol E J
Toward the quiescent coronary plaque.
Journal of the American College of Cardiology 1993;22(4):1228-41.
1993: Lincoff A M; Topol E J
Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
Circulation 1993;88(3):1361-74.
1993: Thomas J D; Topol E J
Wanted: dead or alive. Assessment of myocardial viability after thrombolysis.
Circulation 1993;88(2):797-9.
1993: Douglas J S; Levin D C; Pepine C J; Mullins C E; Block P C; Nissen S E; Brinker J A; Topol E J; Johnson W L; Ullyot D J
Recommendations for development and maintenance of competence in coronary interventional procedures. American College of Cardiology Cardiac Catheterization Committee.
Journal of the American College of Cardiology 1993;22(2):629-31.
1993: Kleiman N S; Ohman E M; Califf R M; George B S; Kereiakes D; Aguirre F V; Weisman H; Schaible T; Topol E J
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
Journal of the American College of Cardiology 1993;22(2):381-9.
1993: George B S; Voorhees W D; Roubin G S; Fearnot N E; Pinkerton C A; Raizner A E; King S B; Holmes D R; Topol E J; Kereiakes D J
Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes.
Journal of the American College of Cardiology 1993;22(1):135-43.
1993: Topol E J; Leya F; Pinkerton C A; Whitlow P L; Hofling B; Simonton C A; Masden R R; Serruys P W; Leon M B; Williams D O
A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group.
The New England journal of medicine 1993;329(4):221-7.
1993: Topol E J; Plow E F
Clinical trials of platelet receptor inhibitors.
Thrombosis and haemostasis 1993;70(1):94-8.
1993: de Feyter P J; van Suylen R J; de Jaegere P P; Topol E J; Serruys P W
Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts.
Journal of the American College of Cardiology 1993;21(7):1539-49.
1993: Topol E J; Bonan R; Jewitt D; Sigwart U; Kakkar V V; Rothman M; de Bono D; Ferguson J; Willerson J T; Strony J
Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Circulation 1993;87(5):1622-9.
1993: Harrison J K; Califf R M; Woodlief L H; Kereiakes D; George B S; Stack R S; Ellis S G; Lee K L; O'Neill W; Topol E J
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group.
Circulation 1993;87(5):1531-41.
1993: Casale P N; Whitlow P L; Franco I; Grigera F; Pashkow F J; Topol E J
Comparison of major complication rates with new atherectomy devices for percutaneous coronary intervention in women versus men.
The American journal of cardiology 1993;71(13):1221-3.
1993: Lee K S; Topol E J; Stewart W J
Atypical presentation of papillary fibroelastoma mimicking multiple vegetations in suspected subacute bacterial endocarditis.
American heart journal 1993;125(5 Pt 1):1443-5.
1993: Lincoff A M; Topol E J
Trickle down thrombolysis.
Journal of the American College of Cardiology 1993;21(6):1396-8.
1993: Topol E J; Ellis S G; Cosgrove D M; Bates E R; Muller D W; Schork N J; Schork M A; Loop F D
Analysis of coronary angioplasty practice in the United States with an insurance-claims data base.
Circulation 1993;87(5):1489-97.
1993: Topol E J
Rotablator to the rescue.
The American journal of cardiology 1993;71(10):858-9.
1993: Chapman G D; Ohman E M; Topol E J; Candela R J; Kereiakes D J; Samaha J; Berrios E; Pieper K S; Young S Y; Califf R M
Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group).
The American journal of cardiology 1993;71(10):783-7.
1993: Granger C B; Califf R M; Young S; Candela R; Samaha J; Worley S; Kereiakes D J; Topol E J
Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
Journal of the American College of Cardiology 1993;21(4):920-5.
1993: Lincoff A M; Topol E J; Chapekis A T; George B S; Candela R J; Muller D W; Zimmerman C A; Ellis S G
Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study.
Journal of the American College of Cardiology 1993;21(4):866-75.
1993: Popma J J; De Cesare N B; Pinkerton C A; Kereiakes D J; Whitlow P; King S B; Topol E J; Holmes D R; Leon M B; Ellis S G
Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy.
The American journal of cardiology 1993;71(7):552-7.
1993: Kalff V; Hicks R J; Hutchins G; Topol E; Schwaiger M
Use of carbon-11 acetate and dynamic positron emission tomography to assess regional myocardial oxygen consumption in patients with acute myocardial infarction receiving thrombolysis or coronary angioplasty.
The American journal of cardiology 1993;71(7):529-35.
1993: Nath F C; Muller D W; Ellis S G; Rosenschein U; Chapekis A; Quain L; Zimmerman C; Topol E J
Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome.
Journal of the American College of Cardiology 1993;21(3):622-7.
1993: Ellis S G; Tcheng J E; Navetta F I; Muller D W; Weisman H F; Smith C; Anderson K M; Califf R M; Topol E J
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.
Coronary artery disease 1993;4(2):167-75.
1993: Topol E J
The restenosis "antitheory".
Mayo Clinic proceedings. Mayo Clinic 1993;68(1):88-90.
1992: Doorey A J; Michelson E L; Topol E J
Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises.
JAMA : the journ